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1. Introduction  
1.1 Overview of Pancreatic cancer 
To date, owing to the soar of mortality rate, pancreatic cancer has become one of the 
most lethal cancers. It occupies the third largest proportion of tumor-associated 
mortality in Western countries.1 When taking all stages into account, 5-year survival 
rates have remained at only around 5% during the last decades.2 
During the year of 2018, approximate 55,440 patients (29,200 men and 26,240 
women) were diagnosed with pancreatic cancer while around 44,330 (23,020 men and 
21,310 women) died of pancreatic cancer in United States.3 Several factors can 
contribute to an increased risk of pancreatic cancer, such as smoking, age, race, 
obesity, diabetes, exposure to certain chemicals (benzene, petrochemicals, dyes, and 
pesticides), gender, inherited genetic syndromes, family history, chronic pancreatitis, 
liver cirrhosis and consumption of alcohol.3 The signs and symptoms are largely 
affected by the stage and the location of pancreatic tumors. As a result of steatorrhea 
and diarrhoea, weight loss and obstructive jaundice usually happen in tumors located 
in the head of the pancreas while tumors of the body and tail elicit abdominal pain and 
weight loss. The pain is normally located in the upper abdomen and radiate to the 
back, presenting as a deep and dull pain. At an early stage of pancreatic cancer, most 
of the symptoms are unspecific, which hinder the early diagnosis of this fatal disease.4  
So far, the exclusive way to obtain curative level is surgical excision which is only 
suitable for less than 20 % of affected patients. These patients are at an early stage of 
the cancer. Locally advanced tumor and metastasis are considered to be the two main 
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counter-indications for surgical intervention. With the improvement of surgical 
techniques, most of the patients whose tumor are recognized as locally restricted 
pancreatic cancer, undergo radical resection of the tumors and have the chance to 
achieve curative results. Since metastasis is a crucial counter-indication for the 
surgical procedure for pancreatic cancer, only chemotherapy and radiotherapy can be 
employed. Consequently, the prognoses for these patients are very poor. That is the 
reason why considerable research focuses on pancreatic cancer metastasis nowadays. 
1, 4 
 
1.2 KRAS mutation in pancreatic cancer 
1.2.1 KRAS and its function 
KRAS is one of most frequent oncogenes which acts as an on/off switch in cell 
signaling. When activated, it regulates cell proliferation. Certain KRAS mutations 
important for pancreatic cancer interrupt negative regulation of cell proliferation. In 
this way, cells ceaselessly proliferate and, ultimately, malignancy develops. 
The gene product of KRAS was first found to be a p21 GTPase.5, 6 There is an 
isoprene group on KRAS’s C-terminus, which contributes to tether the protein to the 
cell membrane. Two proteins named K-Ras4A and K-Ras4B are respectively 
produced in mammalian cells by exon 4A and exon 4B of the KRAS gene. The 
structures of the two proteins differ in their C-terminal region. Besides, they tether to 
cellular membrane including the plasma membrane via different mechanisms.7 
As an on-and-off switch to control molecular, KRAS cycles between the GTP-bound 
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active and the GDP-bound inactive states. Guanine nucleotide exchange factors 
(GEFs) play a key role in the conversion from GDP to GTP, promoting the activation 
of KRAS; however, GTPase-activating proteins (GAPs) elicit the inactivation of 
KRAS, inducing hydrolysis of GTP. Activating mutations of KRAS found in human 
PDAC i.e. pancreatic ductal adenocarcinoma not only whittle down the innate 
GTPase activation by the protein product of KRAS but also cut off the connection 
between KRAS and GTPase-activating proteins (GAPs). There are only three point 
mutation sites of KRAS that drive the development of pancreatic carcinoma. They 
concern amino acids G12, G13 and Q61. Among them, 98% of all KRAS mutations in 
PDAC are point mutations at amino acid G12. The mutations trigger sustained cell 
proliferation, reprogramming of cell metabolism, resistance to apoptosis, reshaping of 
the tumor microenvironment, immune escape, cell migration and metastasis.8 
 
1.2.2 Effector pathways of oncogenic KRAS 
The mechanism of KRAS signaling is rather intricate and changes flexibly every 
second in our body. What matters most here is the recruitment of downstream 
signaling factors, such as canonical Raf/Mek/Erk, phosphatidylinositol 3-kinase 
(PI3K)/3-phosphoinositide-dependent protein kinase-1 (Pdk1)/Akt, 
RalGDS/p38MAPK, Rac and Rho, Rassf1, NF1, p120GAP and PLC-e. It is believed 
that oncogenic signals of KRAS in PDAC transmit by three main pathways: Raf/ 
Mek/Erk, PI3K/Pdk1/Akt and the Ral guanine nucleotide exchange factor pathway9-12 
(Figure 1). 
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Figure 1 Important downstream effectors of the KRAS signaling pathway  
 
1.2.3 Cross-signaling and signaling annuli 
It has lately been recognized that autocrine and paracrine signaling circuits play a 
facilitating role in the amplification of tumorigenic KRAS signaling among different 
tumors.13-15 
Experiments in vivo with PDAC murine models illustrated that when EGFR is 
activated by a KRAS-induced autocrine-positive feedback mechanism, formation of 
acinar-to-ductal metaplasia (ADM) and promotion of early pancreatic intraepithelial 
neoplasia (PanIN) lesions will be induced, which ultimately lead to the development 
of Pancreatic ductal adenocarcinoma (PDAC).13, 14 However, the detailed mechanism 
during the process has not been completely elucidated. We currently believe that the 
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type of regenerative feedback mechanism enhances KRAS signaling and when a 
certain threshold level is reached causing sustained proliferation of pancreatic acinar 
cells, carcinoma develops.13, 15 Apart from KRAS mutation, deletion of p53 also 
results in the generation of PDAC even with only change in EGFR signaling.15 During 
the development of PDAC, severed detailed steps such as for example how loss of 
p53 function decouples KrasG12D from EGFR input are not completely known. 
Similarly, more efforts are needed to uncover whether EGFR signaling makes 
contributions to the formation of PanIN progression and PDAC maintenance and how 
these three elements interplay with each other. As is shown from clinical trials, there 
is a subpopulation (＜10%) of PDAC patients who benefit from treatment with the 
EGFR inhibitor Erlotinib, which raises the question whether a small amount of PDAC 
patients remain addicted to KRAS signaling amplification via EGFR16,17. 
 
1.3 Tumor metastasis 
Cancer metastasis is a complex process that includes different steps such as 
intravasation and extravasation. The majority of tumor cells spread through the body 
via the bloodstream. Plenty of evidence suggests that a small percentage of tumor 
cells survive ultimately once entering into circulatory system and extravasate to 
localize at other organs, also known as distant metastases. Studies in experimental 
murine animal models and mankind tumors have suggested that a plethora of cells 
depart every day from the original site and pass into the bloodstream, but only few of 
them support development of metastases at distant sites.17, 18 This is consistent with 
6 
 
the studies that have monitored the survival of tumor cells after intravenous injection 
in syngeneic mice, which showed that most cells die within 1-2 days,19 while less than 
0.1% of the injected cells eventually form metastases. 
Cancer cells cannot easily survive in the circulatory system, which is mainly owing to 
the attack by the immune system. The anti-tumor effect executed by the immune 
system enormously attenuates the progression of carcinoma.20 Once tumor cells leave 
the original tumor and get into the blood system they will interact with immune cells 
comprising natural killer cells and cytotoxic CD8+ T cells, which play a significant 
role in the elimination of tumor cells. However, tumor cells protect themselves from 
immunological stress via various strategies. Some escape mechanisms are performed 
by the tumor cells themselves, others require interaction with cells such as myeloid 
cells and platelets. Ultimately, tumor cells escape from the hostile intravascular 
environment by transmigrating through the endothelial barrier.21 Various mechanisms 
mediating the different stages of cancer cell extravasation have been identified, 
comprising direct communication of cancer cells with endothelial cells, and indirect 
processes involving blood cells such as platelets and leukocytes.  
After tumor cells extravasation, the cells eventually form a pre-metastatic niche. 
Indeed, the early metastatic niche has already been formed during the first hours after 
tumor cell arrest in the microvasculature according to latest research. Then, these 
niches can either be swept by immune cells or develop into mature metastases after 
several days.22, 23  
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1.4 Blood coagulation 
1.4.1 Overview of the blood coagulation cascade 
In general, the coagulation, anticoagulation and fibrinolysis systems work together to 
maintain homeostasis when blood vessel injury occurs. The coagulation cascade, 
which apart from injury can also be triggered by infections and other conditions, 
induce the formation of fibrin as a final product. In parallel, the anticoagulation 
system is activated to limit the extension of the clot. Thereafter, fibrinolysis system 
comes into work to resolve the fibrin-rich thrombi. Essentially, the coagulation 
cascade activation consists of a complicated set of biochemical mechanisms triggering 
zymogens to become active and to amplify these interactions, which in the end result 
in the switching from soluble fibrinogen to insoluble fibrin. The coagulation cascade 
can be activated by two classical pathways: one is the contact pathway and the other 
is the tissue factor (TF) dependent pathway (Figure 2). 
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Figure 2 Blood coagulation cascade. See Ref 24 
 
The contact of blood with negative charges on artificial materials can convert 
zymogen Hageman factor (Factor XII) to the active enzyme FXIIa, which 
successively activates FXI to FXIa that in turn activates FIX to FIXa. The latter 
proteinase can be part of the tenase complex with FVIIIa to trigger downstream 
formation of FXa. In general, the TF-dependent pathway is the more crucial pathway 
in blood coagulation under biological and physiological conditions. TF is widely 
expressed in different types of subendothelial cells, and once the protein gets in 
contact with blood it will immediately form a complex together with FVII/FVIIa. This 
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TF-VIIa complex can either trigger the conversion of FIX to FIXa, which enhances 
the intrinsic pathway, or directly activate factor X. FXa, FVa, prothrombin and Ca2+ 
ions form the prothrombinase complex to convert prothrombin into thrombin, which 
in turn converts fibrinogen to fibrin. The clots finally formed not only contain fibrin 
polymers but also platelets, RBCs and/or WBCs. There are three important positive 
feedbacks in the coagulation cascade, which aim to amplify and accelerate the 
formation of thrombus in response to injury. One has been referred above, the other 
two are that thrombin can activate FVIII and FXI into FVIIIa and FXIa respectively, 
which are considered as one of the most important way to trigger the intrinsic 
pathway under physiological conditions.24, 25  
 
1.4.2 Role of FXII in blood coagulation 
The contact pathway of blood coagulation is triggered by FXII, together with 
kininogen (HK) and plasma kallikrein (PK). When getting in contact with surfaces 
rich in negative charges, zymogen FXII changes its conformation, resulting in a few 
FXIIa (molecules). Then, FXIIa activates PK, which in turn increase activation of 
FXII. Similar to other contact system proteins, such as PK and HK, deficiency in FXII 
severely prolongs the activated partial thromboplastin time (aPTT), a diagnostic 
coagulation assay that relies on contact system activation. However, patients with 
severe deficiencies in FXII, PPK or HK do not suffer from spontaneous or 
injury-related excessive bleeding, in contrast to deficiency in TF, VIII and IX, which 
means that activation of FXII is dispensable for the process of haemostasis. However, 
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new insights in FXII have emerged in the last decade due to the observation that f12-/- 
mice appear to be protected from arterial thrombosis26, 27. Several triggers contribute 
to FXII activation during thrombosis, in particular extracellular RNA, and or exposed 
collagen in the arterial wall 28, 29. Taken together, several studies suggest that FXIIa 
inhibitors may reduce the extent of arterial thrombosis in vivo. 
The contact system has drawn strong scientific attention as a result of its contribution 
to pathological thrombosis formation. However, this system has also been involved in 
inflammatory reactions. Taking sepsis patients as an example, inhibition of the contact 
system attenuates complement activation and reduces neutrophil degranulation. 
Consequently, overall survival rates increase.30 Nevertheless, the role of FXII in 
tumor extravasation and metastasis is still ambiguous and needs to be investigated. 
 
1.4.3 Cancer and thrombosis 
The occurrence of cancer is accompanied by an increase of the incidence of venous 
thromboembolism (VTE) (4% to 20%) and arterial thrombosis (2% to 5%);31-33 the 
rates of VTE are dependent on the cancer type.32, 34, 35 Based on a risk assessment of 
VTE, the type of cancer can be roughly split into 3 classes: the first class is high risk, 
which includes pancreatic cancer, ovarian cancer, brain cancer, stomach cancer, 
gynecologic cancer, and hematologic cancer; the second is intermediate risk, 
consisting of colon cancer and lung cancer; the third is low risk, comprising breast 
cancer and prostate cancer. Many previous studies have attempted to elucidate why 
tumor can activate blood coagulation and thus cause VTE. One obvious reason is that 
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tumor cells themselves can directly induce blood coagulation and fibrin formation. It 
is less clear whether also the host triggers coagulation in response to tumor cells.  
As an example, human pancreatic cancer express larger amounts of TF than the 
normal tissues and the expression of TF is relevant to the histologic grade of tumors.36 
One study showed that there is an association between intra-tumoral TF expression 
and VTE.37 In addition, human pancreatic cell lines also express high levels of TF and 
release TF+ extracellular vesicles (EV).38 MVs (also known as microparticles) are 
released from pancreatic cancer cells which are activated or apoptotic as small 
membrane vesicles39. They are procoagulant by providing a surface for the assembly 
of different coagulation factor complexes.40 When negatively charged phospholipids 
such as phosphatidylserine (PSer) are exposed on the vesicle membrane, the 
procoagulant activity of MV is enhanced. Dvorak et al first proposed a connection 
between tumor-derived MV and thrombosis.41 They showed that deciduous vesicles 
have procoagulant activity, facilitating fibrin deposition. Late studies showed that 
enhanced procoagulant activity of the MV derived from malignancy is 
TF-dependent42, 43. 
Meanwhile, it is believed that leukocytosis may be associated with increased VTE in 
tumor patients as well.44, 45 For example, neutrophils may promote the formation of 
thrombosis by generating neutrophil extracellular traps (NETs),46 while monocytes 
synthesize TF themselves.47 Thrombocytosis is a common phenomenon for tumor 
patients, especially those who are diagnosed with ovarian, breast, lung, and 
gastrointestinal cancer. Patients with high platelet counts have a higher rate of 
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developing VTE in the absence of cancer, meaning that the level of peripheral blood 
platelet counts is directly proportional to the incidence of VTE.48 Interestingly, a 
similar phenomenon may be relevant in tumor patients, namely cancer patients with 
high platelet counts had a higher rate of developing VTE.49, 50 However, the 
underlying mechanisms for leukocytosis and thrombocytosis in cancer patients are 
still unclear today. 
 
1.5 Monocytes, inflammation and Cancer 
Monocytes are a type of circulating leukocyte that can differentiate into several types 
of the immune cells including macrophages and dendritic cells, which together form 
the “mononuclear phagocyte system” (MPS).51 Monocytes are generated in the bone 
marrow and are continuously released into the peripheral circulation where they play 
a crucial role in tissue homeostasis and immunity.52 During the past 4 decades, our 
knowledge about the characteristic of monocytes has evolved from considering them 
as a homogenous group to their appreciation as a heterogeneous population, which 
has diverse functions in the immune response. Nowadays, three subgroups of 
monocytes are known based on the quantity of their surface markers:1) classical 
monocytes or inflammatory monocytes (CD14+CD16- in human, 
Ly6ChighCD43lowCX3CR1low in mice); 2) non-classical monocytes or patrolling 
monocytes (CD14lowCD16+ in human, Ly6ClowCD43 highCX3CR1high in mice); 3) 
intermediate monocytes (CD14+CD16+ in human, Ly6CintCD43 highCX3CR1high in 
mice). The percentage of classical and non-classical monocytes are species-dependent, 
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for example classical monocytes dominate in humans.53 Circulating monocytes are 
recognized to originate from the bone marrow after birth, sharing common myeloid 
progenitors (CMPs) with red blood cells, platelet, and granulocytes. Monocytes have 
long been considered to be the main source of tissue resident macrophages. However 
tissue-specific macrophages can also originate from yolk sac during embryogenesis 
and migrate to the fetal liver to become fetal hepatomacrophages, which can then 
disseminate to various organs on the condition that the fetal circulation exists.54 After 
residing in the tissue, they maintain themselves via self-renewal, which is the main 
resource of tissue resident macrophages.55  
Classical monocytes, which are rapidly recruited after infection or inflammation, only 
remain for about one day in the peripheral blood. They can either migrate to the tissue 
to repopulate the tissue specific monocytes or lose the Ly6C marker to get converted 
into non-classical (patrolling) monocytes. Non-classical monocytes have a longer 
lifespan than classical monocytes, which are approximately 2 days in mice and 7 days 
in humans. The most important function of non-classical monocytes is to patrol and 
survey the endothelium as a local innate surveillance under physiological 
conditions56-58.  
In cancer, monocytes can accompany each stage of the disease, from early growth to 
the establishment of metastasis59, 60. Inflammatory monocytes are in particular 
precursors of tumor-associated macrophages (TAMs). The appearance of TAMs 
correlates with a poor prognosis in the majority of clinical studies and animal 
models61, 62. Non-classical monocytes, on the contrary, which are recruited and 
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localized in microvessels after injection of tumor cells, attenuate tumor metastasis 
such as via recruitment of NK cells63, 64.  
 
1.6 Neutrophils and neutrophil extracellular traps (NETs) 
Neutrophils make up the largest proportion of innate immune cells in the human 
immune system. They are equipped with broadly effective antimicrobials that are 
stored predominately in specialized granules. Beside this, the neutrophil arsenal can 
also cause injury to host tissues. Deployment of these cells sets in motion three major 
antimicrobial strategies: phagocytosis, degranulation and the release of NETs. The 
releasing process of NETs is called NETosis (Figure 3), which is clearly different 
from necrosis or apoptosis and was first discovered by Brinkmann et al. 46 NETs are 
extracellular strands of decondensed (unwound) DNA decorated with histones and 
neutrophil granule proteins.46, 65  
DNA is wrapped around histones to form nucleosomes and further organized into 
chromatin. Heterochromatin de-condensation is mediated by peptidyl arginine 
deiminase 4 (PAD4), which catalyzes the conversion of histone arginines to citrullines, 
reducing the strong positive charge of histones and consequently reducing 
histone-DNA binding. This weakened interaction subsequently unwraps the 
nucleosomes, a prerequisite for NETs formation. In case of PAD4, neutrophil elastase 
(NE) is also regarded as a crucial factor that contributes to the formation of NETs, 
since it can cleave histones during this process.66, 67 
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Figure 3 Process of NETs formation. See Ref68 
There is a large body of evidence showing that the generation of NETs is essential to 
the incidence of carcinoma. Some murine models with cancer injections have 
suggested that when microorganisms such as bacteria enter the blood stream or tissue 
injury by surgery is sensed, NETs will be produced and released in the circulation 
system, which in turn promotes the formation of distant metastasis. NETs can catch 
tumor cells.69, 70 NETs within the blood vessel were shown to increase the vessel 
permeability, facilitating for tumor cells to diffuse out of the blood stream. What’s 
more, NETs facilitate the process of epithelial-to-mesenchymal transition through 
degeneration of vascular endothelial cadherin and the promotion of the β-catenin 
signalling pathway.71 In contrast, Millrud et al. suggested that the amount of 
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recruitment of neutrophils that has a strong ability to secret NETs, was accompanied 
by better survival in patients with head and neck squamous cell carcinoma,72 which 
suggests, to some extent that, NETs had killed the tumor cells. Based on abundant 
studies which focus on the function of NETs in tumor formation, it is widely accepted 
that NETs are crucial in the process of development of primary tumors, tumor cell 
extravasation and distant metastasis; whereas, whether the function of NETs is pro- or 
anti- metastatic is still not clear and needs to be further investigated. 
 
1.7 Extracellular vesicles (EVs) 
1.7.1 Overview of extracellular vesicles 
EVs are small globular particles encircled by a lipid bilayer with different diameters 
(from 30 nm to a few μm), which can be secreted by any type of cell and can be 
detected in all body fluids. EVs can perform multiple biological functions and can 
affect the microenvironment by the horizontal transfer of bioactive molecules such as 
proteins, lipids, DNA, and RNA.73, 74 The description of EVs began in the late 1960s 
and  researchers found that EVs could affect coagulation or to contain 
calcification-inducing factors in plasma or bones.75, 76 In the 1970s and 1980s, terms 
like microparticles,77 microvesicles,78, 79 ‘membrane fragments’80 and ‘membrane 
vesicles’ 81, 82 were used to depict vesicles produced by cultured tumoral and 
non-tumoral cell lines. At that time, EVs were assumed to be released by outward 
budding of the cells’ plasma membrane. In the early 1980s, a more complex EVs 
secretion pathway was described, in which vesicles initially formed intracellularly 
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within so-called multivesicular endosomes (MVE) or multivesicular bodies (MVBs) 
from which they were subsequently secreted. After then, the word exosomes was used 
to describe EVs released from MVE.83 During the end of 1990s, two studies on 
antigen-presenting cells appeared, revealing that the existence of surface molecules on 
exosomes may play a part in the signalling pathway in acceptor cells; therefore, they 
not merely function as ‘dust bins’, but are messengers in pathway signaling as well; 
surprisingly, before that, MVs and other shed membrane vesicles have been studied 
for their functions in cell-cell communications for quite a long time.84, 85 
 
1.7.2 Role of EVs in tumor growth and metastasis 
Tumor cells can release several types of EVs, which differ in terms of size, biogenesis 
and molecular compositions. Specifically, these are exosomes, which are nano-sized 
EVs (30-100 nm) that are derived from MVBs and released by fusion with the plasma 
membrane. MVs are larger EVs than exosomes and are derived from the surface of 
cells. They originate from the plasma membrane. Apoptotic bodies are particles of a 
relatively large size (1-4 μm), and are released by apoptotic cells. Finally, large 
oncosomes (LOs), which are representative of an extra type of EVs originated from 
tumor cells, possess an atypical larger size compared to the particles previously 
mentioned and are rich in tumor cell-derived nucleic acids. 83, 86-88  
The formation of LOs is especially easily detected in highly migratory, aggressive 
tumor cells with an amoeboid phenotype.88, 89 They are products of non-apoptotic cell 
membrane blebs used by amoeboid cells as promoters of migration.90 Measurements 
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of the LOs size have uncovered that though the LOs diameter vary from 1 to 10 μm, 
the average diameters is 3–4 μm. LOs can only be produced by tumor cells, and the 
very little expression level in non-tumor cells can be neglected. LOs detachment can 
be detected commonly in distinct kinds of tumors, including prostate, breast, bladder, 
and lung cancer. To date, LOs have been successfully detected in the blood stream of 
mice and patients with metastatic prostate cancer, indicating that LOs may be a 
potential candidate for clinical biomarkers of tumor diagnosis.89, 91 
Recent studies suggest that interactions between EVs and cells in the tumor 
microenvironment are significant for tumor progression and metastasis. Cancer 
associated fibroblasts (CAFs) are one of the most frequent cell type in the tumor 
microenvironment. Upon exposure to cancer cells, CAFs change their phenotypes.92 
In turn, when CAFs get in touch with tumor cells in cell culture media, they will 
become increasingly aggressive, which might depend on CAF-induced stemness and 
metabolic reprogramming.93 Tumor cells and fibroblasts can both produce a variety of 
EVs, which take part in the reciprocal interaction with the two cells, and this plays a 
significant part in tumor progression. 
It is currently assumed that exosomes produced by tumor tissues can regulate the 
structure of stroma to support the progression of tumors by providing nutrition 
support from the blood stream and by promoting proliferation of transformed cells.94 
Furthermore, some tumor exosomes can induce fibroblasts to differentiate into CAFs, 
which strengthen the aggressiveness of tumor cells. More and more focus has been 
placed on the role of cancer-derived microvesicles on the tumor microenvironment. 
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Tumor microvesicles have been regarded as enhancers of the proteolytic cascade 
allowing cancer cells to degrade the extracellular matrix and invade the surrounding 
environment.95 Antonyak and colleagues demonstrated that microvesicles, generated 
from various human cancer cells (like breast carcinoma and glioma cells) can alter the 
characteristic of normal fibroblasts and prolong their survival which is similar to the 
transformed cells.96 
The interactions between tumor cells and immune cells are also important for the 
emergence of the tumor microenvironment. Immune cells can capture EVs originating 
from tumor tissues, resulting in either immune escape or immune suppression. Which 
subsets of EVs regulate the immune system, and the detailed functional mechanisms 
at the molecular level underlying the transfer and immune cell modulation by 
receptors, proteins, RNA, and DNA carried in EVs, are still largely unclear. 
Nevertheless, the education of immune cells by cancer-generated EVs, might be target 
for the preparation of cancer vaccines and for investigations of novel cancer therapies. 
Monocytes are an acceptor cell for cancer-generated EVs in the tumor 
microenvironment. Baj-Krzywirzeka and colleagues97 have identified a series of cell 
surface markers and mRNA transcripts in EVs from pancreatic adenocarcinoma 
(HPC-4), colorectal carcinoma (DeTa) and lung carcinoma (A549) cells and they have 
found that IL8, VEGF, HGF, and CD44 mRNA were expressed at high levels in EVs, 
suggesting a profound functional significance for these signaling mediators in 
monocyte re-education. Moreover, the communication of EV cell surface proteins 
with monocytes alters the production level of CCR6 and CD44 and activates Akt, 
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causing more chemotaxis and longer cell survival. This may lead to the migration of 
monocytes into the tumor tissue, where monocytes can differentiate into 
tumor-associated macrophages (TAMs) and support tumor formation, amplify local 
tumor progression, and facilitate distant metastasis.98 The invasion and persistent 
colonization of tumor MVs in liver tissue can be regulate by CD36, a lipid receptor, 
which has already shown to mediate the engulfment of cancer MVs by myeloid 
cells.99 
Angiogenesis is an important step in cancer progression. Construction of the tumor 
vascular network is rather important for sustained signaling of cell proliferation 
because tumor cells absorb oxygen and nutrients and eliminate useless metabolite via 
the blood channel. When distant metastasis is undergoing, the support of vasculature 
seems more indispensable for the tumor cells because it helps tumor cells get into the 
blood vessels and eventually settle down in another organ. Noticeably, exosomes 
produced by tumor tissues comprise key pro-angiogenic factors closely related to 
endothelial cell migration and the newly-born blood vessel formation, such as 
Vascular Endothelial Growth Factor (VEGF), which is overexpressed in the majority 
of tumors.100 Recent studies have demonstrated that tumor exosomes contribute to 
angiogenesis by transferring also mRNAs101. 
 
1.8 Mediators of tumor cells extravasation  
1.8.1 Ang/Tie signaling pathway 
Angiopoietins, ligands of the Tie-2 receptor, which is a tyrosine kinase receptor 
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composed of immunoglobulin and epidermal growth factor homology domains, 
control blood vessel development and stability.102 So far, four different angiopoietins 
have been discovered: Ang-1, Ang-2, Ang-3 and Ang-4. As shown in figure 4, the 
angiopoietins generally consist of an N-terminal super clustering domain (SCD), a 
central coiled-coil domain (CCD) for ligand homo-oligomerization, a linker region, 
and a C-terminal fibrinogen-related domain (FReD) for binding to the Tie-2 receptor. 
Ang-1 and Ang-2 can form dimers, trimers and tetramers. Moreover, Ang-1 can 
assemble into higher order multimers via its SCD. Tie-2 can be only activated by 
tetrameric or higher multimeric forms of Ang-1. Oligomeric Ang-2 can be a weak 
agonist of Tie-2.103, 104  
 
Figure 4 Structure of Tie-2 receptor, Angiopoietin and Ang/Tie-2 binding. Ref 105. 
The Ang/Tie-2 signaling is essential for blood vessel remodeling and for the 
recruitment of vessel wall cells and blood vessel maturation during embryonic 
development and adult vessel homeostasis.106 Ang-1 is predominantly expressed in 
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perivascular cells such as pericytes, vascular smooth muscle cells, fibroblasts and 
tumor cells.107, 108 After binding of Ang-1 to Tie-2 receptor, Tie-2 receptor is activated, 
which can further stimulate numerous downstream intracellular signaling pathways. 
Consequently, it will promote the survival of endothelium cells (ECs), the 
maintenance of an endothelium barrier and a quiescent vasculature.109, 110 Ang-2 is 
mainly produced by ECs and its expression is manipulated by various growth factors 
at the mRNA expression level.111, 112 Ang-2 is usually preserved in endothelial 
Weibel-Palade bodies and can be quickly secreted in response to phorbol esters, 
thrombin, and histamine. Ang-2 seems to work mainly as an antagonist for Ang-1 by 
replacing the more active ligand Ang-1 from the Tie-2 receptor.113 Ang-2 can 
destabilize the endothelium in an autocrine manner and this effect can be counteracted 
by Ang-1. Therefore, the ratio of Ang-1 to Ang-2 is critical in balancing Tie-2 
receptor mediated signaling and regulating vascular homeostasis.114 
 
1.8.2 Ang/Tie-2 signaling and tumor progression 
It is still controversial whether Ang-1 and Ang-2 can contribute to tumor growth or 
tumor-induced angiogenesis. The expression of Ang-1 is upregulated in different 
types of cancers, while a clear correlation with tumor malignancy has never been 
shown. Moreover, overexpression of Ang-1 in different tumor cells and in tumor 
models can have different effects. In some cases, the growth rates have been 
dramatically increased. In contrast, they are reduced in other cases.  
It is generally accepted that Ang-2 expression is elevated in many human cancers and 
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high serum expressions of Ang-2 correlate with increased blood vessel density in 
tumors, tumor metastasis and a poor survival rate. A number of studies carried out in 
several pre-clinical murine animal models have shown that blocking Ang-2 inhibits 
tumor growth and tumor blood vessel sprouting.115 Additionally, blocking Ang-2 
ameliorates tumor lymphangiogenesis and improves the “normal” vessel phenotype 
by increasing pericyte coverage and the levels of adhesion molecules in EC-EC 
junctions. Blocking Ang-2 also reduces tumor metastasis by inhibiting early 
metastatic growth and by improving blood capillary EC junctions, thereby inhibiting 
tumor cell extravasation into the lungs.116, 117 
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2. Objectives of the thesis 
As previously referred to, patients with tumors are more likely to develop thrombotic 
diseases.31, 35Thus, anticoagulant therapies are usually employed to prevent these 
complications. It is still unclear, what kind of role blood coagulation plays in tumor 
extravasation and metastasis. The following questions will be addressed in this thesis. 
1. What are the mechanisms of tumor-induced blood coagulation and which role do 
they play in tumor cell extravasation and metastasis? 
2. How does host-induced blood coagulation in response to circulating tumor cells 
affect tumor cell movements and what are the underlying mechanisms? 
3. What are the effects of EVs, in particular of LOs, on the prometastatic effects of 
tumor cells? 
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3. Materials and methods 
3.1 Materials 
3.1.1 Equipment 
Items  Company, Type 
Balance MC1 LC 620 S Sartorius (Göttingen, D) 
Cell culture incubator    Binder, Serie C 
Cell culture microscope  Zeiss, Axiovert 100 
Count chamber Neubauer Improved Brand (Wertheim, D) 
Culture Hood  
ThermoScientificTM  
MSC-AdvantageTM 
Pipet boy Integra-Bioscience (Biebertal, D) 
Serological pipette (5ml, 10ml, 25ml) Omnilabs 
Micropipettes (10µl, 20µl, 100µl, 200µl, 1000µl) Eppendorf (Hamburg, D) 
Centrifuge (Mikro 22R, Rotina 35R, Universal 
32) Hettich 
Ultracentrifuge Beckman, OptimaTM, LE-80K 
Thermomixer R Eppendorf 
Electrophoresis unit 
Invitrogen, XCell SureLock® Mini-Cell 
und das XCell II™ Blot-Modul 
Electrophoresis power supply BIO-RAD, POWER PAC 300 
Film development machine for Western Blot CURIX60, AGFA 
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Multi-Mode Detection Platform SpectraMax, Molecular Devices 
Cryotome Machine Leica CM3050 
LSM 510 Meta  Zeiss (Jena, D) 
Lamin Air flow HLB 2472 Thermo Scientific (Braunschweig, D) 
Thermocycler  Applied BiosystemsTM 
Nano Drop Thermofisher 
Real-Time PCR Detection System BIO-RAD 
pH meter  HANNA instruments HI 221 
Thrombelastograph  RoTEG Dynabyte 
Items Company, Type 
Vortexer Sartorius (Göttingen D) 
Water bath Julabo U3 Julabo Labortechnik (Allentown, USA) 
 
3.1.2 Kits 
Item Company Catalog number 
Antibody Labelíng Kit Alexa488 Life/Thermo    A-20181 
Antibody Labeling Kit, Alexa555 Life/Thermo    A-20187 
  Plasmid Maxi Kit (10)    Qiagen    12362 
High-Capacity RNA-to-cDNATM Kit Thermofisher 4387406 
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3.1.3 Primary antibodies 
Antibody Reactivity Concentration Host Company Catalog number 
CD4  mouse 1:100 rat Biolegend 100442 
CD8a mouse 1:100 rat Biolegend 100702 
CCR3 mouse 1:250 rabbit Cell Singaling 9664 
CD45 mouse 1:50 rat AbD Serotec MCA1031GA 
MPO mouse 1:100 rabbit abcam ab9535 
Anti-Histone H3 mouse 1:100 rabbit abcam Ab18521 
Angiopoietin I mouse 1:400 rabbit abcam ab8451 
Angiopoietin II mouse 1:400 rabit abcam ab8452 
ß-actin mouse 1:3000 rabit abcam ab179467 
PADI4 mouse 1:1000 rabbit Sigma-Aldrich SAB2101710 
SLC9A2 mouse 1:1000 rabbit Invitrogen TK2678666 
mNKp46 mouse 1:500 goat Biolegend AF2225 
FXII mouse 1:250 rabbit Invitrogen PA5-76120 
TF (1H1) mouse 1:50 rabbit Gentech-Roche 
(Rotkreuz, CH) 
18350-01 
CX3CR1 mouse 1:100 rabbit Novus Biologicals bs-1728R 
CX3CR1-FITC mouse 1:100 - Biolegend 149020 
F4/80 mouse 1:200 rat Biolegend 123102 
Fibrin mouse 1:100 mouse WAK NYBT2G1 
Ly6C mouse 1:400 rat Thermofischer 1804 
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Ly6G mouse 1:50 rat BD Biosciences 551459 
Mouse IgG mouse 2µg/ml mouse Vector BA9200 
Rabbit IgG rabbit 2µg/ml rabbit Vector I-1000 
Rat IgG mouse 2µg/ml rat Vector I-4000 
GAS6 mouse 1:50 rabbit Santa Cruz sc-376087 
Stabilin II mouse 1:100 mouse Invivo Biotech AK2810/01 
 
3.1.4 Secondary antibodies 
Antibody Reactivity Concentration Host Company Catalog number 
Alexa488 mouse 1:1000 donkey Life Technologies 1915874 
Alexa488 rat 1:1000 goat Life Technologies 1814724 
Alexa488 rabbit 1:1000 goat Life Technologies 1937195 
Alexa448 goat 1:1000 donkey Life Technologies A32841 
Alexa546 mouse 1:1000 goat Life Technologies 1809360 
Alexa546 rat 1:1000 goat Life Technologies 1848462 
Alexa546 rabbit 1:1000 goat Life Technologies 1904467 
Alexa594 mouse 1:1000 goat Life Technologies 1579585 
Alexa594 rat 1:1000 goat Life Technologies A11007 
Alexa594 rabbit 1:1000 goat Life Technologies 1981132 
IgG-HRP rabbit 1:5000 chicken Santa Cruz Sc-2955 
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3.1.5 Buffers 
Blocking buffer 
1x PBS 
0.1 % Tween 20 
2% / 5 % / 10% BSA (as per protocol) 
 
CaCl2 (Faktor Xa Formation; 50ml) 
225 mg CaCl2 .2H2O 
ddH2O  
 
Ca/Hepes (TEG)  
10 mM Hepes 
100 mM CaCl2,  
ddH2O, pH 7,4  
 
 ZnCl2 (Factor XIIa Formation) 
    10 mM ZnCl2 
ddH2O 
 
PBS (Phosphate Buffered Saline) (1L) 
8 g NaCl 
0.2 g KH2PO4 
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1.42 g Na2HPO4.2H2O 
0.2 g KCl 
 
Permabilisation/ Blocking-Buffer 
0.5 % BSA 
0.1 % Triton   
Sterile filtered 
 
TNC (Tri-Nitrium Citrate for blood drawing) 
3.68 g TNC 
100 ml ddH2O 
Sterile filtered 
 
SDS-PAGE running buffer (1L) 
50ml NUPAGE SDS MOPS 20X 
950ml ddH2O 
 
Resuspension buffer (1L) 
138 mM NaCl 
2.7 mM KCl 
12 mM NaHCO3 
0.4 mM NaH2PO4 
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1 mM MgCl2.6H2O 
5 mM D-Glucose 
5 mM Hepes 
pH 7.35 
 
Tryphan Blue in PBS (cell counting and LOs counting) 
0.4% Tryphan blue 
1 mM Ca2+ 
ddH20 
 
SDS-PAGE transfer buffer (250ml) 
      12.5 ml NUPAGE Transferbuffer 20X 
250 µl NUPAGE Antioxidant 
50 ml Methanol 
ddH2O 
 
Blocking buffer for WB membrane (1L) 
       100 ml 10X TBS 
1 ml Tween 20 
50 g non-fat dry milk (BSA) 
900 ml distilled water 
Filter with 0.2 mm Whatmann filter paper 
32 
 
 
Washing buffer for WB membrane (1L) 
100ml 10X TBS 
3 ml Tween 20 
 
3.1.6 Cell lines 
Cell Line ID Sample location Host Genomic Kras status 
5320 Primary pancreatic tumor mouse CN-LOH 
16990 Primary pancreatic tumor mouse het 
S134 Primary pancreatic tumor mouse amp-focal 
53631 Primary pancreatic tumor mouse amp-arm 
8028 Primary pancreatic tumor mouse CN-LOH 
8182 Primary pancreatic tumor mouse het 
8305 Primary pancreatic tumor mouse amp-arm 
8570 Primary pancreatic tumor mouse CN-LOH 
8661 Primary pancreatic tumor mouse amp-arm 
9091 Primary pancreatic tumor mouse CN-LOH 
9203 Primary pancreatic tumor mouse het 
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3.1.7 Mouse models 
C57BL/6 M/F 21-25 G ca. 8+ weeks Charles River 
C57BL/6J-F12tm1, M/F 21-25 G ca. 8+  
weeks            
Institute of Experimental Biomedicine Chair I, 
University of Würzburg, Germany 
C57BL/6Nur77-/-, M/F 21-25 G ca. 8+  
weeks            
Department of Physiology, University of Santiago de 
Compostela, Spain 
 
3.1.8 Reagents and chemicals 
Item Company      Catalog 
number 
Aceton 99,5% PA Carl Roth   9372.2 
Acrylamide bis-Acryl Sigma-Aldrich A3699 
Beriplex   CSL Behring   Apotheke 
Cell culture Flasks: 175cm2 straight neck  BD Pharmingen 353112 
Cell culture Flasks: 25cm2  straight neck  BD Pharmingen 353107 
Chromogene Substrate S-2222  Haemochrom 
Diagnostic 
41201 
CTI (Corn Trypsin Inhibitor)  Calbiochem 650345 
DAKO Pen für Immunocytochemie Dako Cytomation S200230 
Desirudin (S.cerevisiae) AFl 15mg Inresa REVASC  
DMEM 1g/l Glucose Life/Thermo 31885-023 
34 
 
DMEM 4.5g/l Glucose Life/Thermo 41965-039 
DMSO Hybri-Max Sigma-Aldrich D2650 
Duramycin-LC-Biotin Mol. Targeting Techn. D-1003 
Essigsäure / Acetic acid Carl Roth 3738.1 
Ethanol Vergällt 99,8%  Carl Roth K928.3 
FBS Thermofisher 10270106 
Freezing Medium  Ibidi 80023 
Gelantin 2% Solution Sigma-Aldrich G1393-20ML 
HCl REINST 37% Carl Roth 9277.1 
Kaliumhydroxid Potassiumhydroxid Carl Roth 3904.1 
Lipofectamine 3000 Reagent Life/Thermo    L3000008 
Mayer´s Hematoxylin Science Service GmbH 26381-02 
MEM alpha Medium Life/Thermo 22571-020 
Methanol reinst >99,5% Carl Roth CP43.4 
Multiwell: 12-well  BD Pharmingen 353225 
Multiwell: 24-well  BD Pharmingen 353226 
Multiwell: 6-well  Omnilab 353046 
Multiwell: 96-well BD Pharmingen 353072 
NaCl 1KG Carl Roth P029.2 
NaOH Plätzchen Roth 041300 
Objektträger SuperFrost Omnilab J1800AMNZ  
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OPTI-MEM(1X) + L-GL. Life/Thermo 31985-047 
PBS Sigma-Aldrich D8537 
Penicillin/Streptolysin (100X) Invitrogen 15140-122 
Pipette serol, Wattestopf.einzeln 10ml Omnilab 4488 5380582 
Pipette serol, Wattestopf.einzeln 5ml Omnilab 4487 606180 
Poly-L-Lysine Solution Sigma-Aldrich P8920-100ML 
Protease Inhibitor Set 10 Stk Roche 11206893001 
Protein Assay Reagent A BioRad 500-0113 
Protein Assay Reagent B  BioRad 500-0114 
Puromycin DIHCI VWR 540411-25MG 
Eppi-Cup Safe-Lock farbl.   1,5ml Eppendorf 0030120086 
Eppi-Cup Safe-Lock farbl.   2ml Eppendorf 0030120094 
Roteg-Küvetten (Cup and Pin pro) 2 Rotem 200011 
Sodium Carbonate Anhydrite Sigma-Aldrich S7795-500G 
SYTO 62 Life/Thermo S11344 
Thromborel S 400T Siemens Healthscare OUHP29 
Tissue Tek T-TEK Hartenstein TTEK 
Trypan Blue Carl Roth CN76.1 
Trypsin-EDTA Solution (10X) Sigma-Aldrich 59418C 
Tween20 (Polyoxethylene) Sigma-Aldrich P1379-100ML 
Vectashield Hard Set with DAPI Linaris H-1500 
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Vectashield with DAPI  Enzo/Life/Thermo VC-H-1200-L010 
Water Tissue culture tested Sigma-Aldrich W3500-500ML 
ZnCl2  Sigma-Aldrich 208086-5G 
Human FXII  HTI GG-1218 
Chromogene Substrate S-2302 
Haemochrom 
Diagnostic 41205 
R428 Selleckchem S2841 
FXII deficient plasma CellSystems 561404 
FVII deficient plasma Siemens Healthscare 504740 
NucleoZOL MACHEREY-NAGEL 740404.200 
RNase-free water   Invitrogen    AM9935 
2-Propanol Sigma-Aldrich 278475 
PowerUp™ SYBR™ Green Master Mix 
(2X) Applied bio systems A25741 
Actb Mouse qPCR Primer Pair ORIGENE NM_007393 
Gapdh Mouse qPCR Primer Pair ORIGENE NM_008084 
Padi4 Mouse qPCR Primer Pair   ORIGENE   NM_011061 
Slc9a2 Mouse qPCR Primer Pair ORIGENE NM_001033289 
pLKO.1-puro Padi4 shRNA Plasmid DNA Sigma-Aldrich 04241817MN 
pLKO.1-puro Non-Target shRNA Control 
Plasmid RNA Sigma-Aldrich SHC016-1EA 
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SilencerTM Pre-designed SLC9A2 siRNA Thermofisher 284094 
SilencerTM Negative Control siRNA Thermofisher AM4635 
NuPAGETM 4-12% Bis-Tris Protein Gels Invitrogen NP0335BOX 
RIPA Lysis and Extraction Buffer Thermofisher 89901 
Protease Inhibitor Thermofisher 36978 
NuPAGETM Antioxidant Invitrogen NP0005 
NuPAGETM MOPS SDS Running Buffer Invitrogen NP0001 
NuPAGETM Transfer Buffer Invitrogen NP00061 
SuperBlockTM (TBS) Blocking Buffer Thermofisher 37535 
PierceTM ECL Western Blotting Substrate Thermofisher 32106 
ECLTM Prime Western  Blotting System Sigma-Aldrich GERPN2232 
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3.1.9. Primer for Qpcr 
gene   Sequence (5’-3’) 
Mus GAPDH          F  GATCATCAGCAATGCCTCCT 
  R  TGTGGTCATGAGTCCTTCCA 
Mus β-Actin                 F  ACCAACTGGGACGACATGGAG 
  R  TAGCACAGCCTGGATAGCAAC 
Mus Gapdh F  CATCACTGCCACCCAGAAGACTG 
 R  ATGCCAGTGAGCTTCCCGTTCAG 
Mus Actb F  CATTGCTGACAGGATGCAGAAGG 
 R  TGCTGGAAGGTGGACAGTGAGG 
Mus Slc9a2 F  GTGTCCACTGTTGGGAAGAACC 
 R  ACTGGTCCTTGAAGGTTAGCGG 
Mus Padi4 F  ACGCTGCCTGTGGTCTTTGACT 
 R  ACCTCCAGGTTCCCAAAGGCAT 
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3.2 Methods 
3.2.1. Animal experimentation protocol 
Mice were in general purchased from Charles River Laboratory and housed under 
specific pathogen free conditions at the animal facility of Walter Brendel Centrum. 
The mice used for all experiments were aged from 9 weeks to 14 weeks. Mice were 
sacrificed by strangulating the neck and subsequently the organs were collected. All 
experiments involving mice were conducted with approval by the local Animal 
Experimentation Committee (Regierung of Oberbayern, Munich). All experiments 
were performed in accordance with the ARRIVE guidelines and regulations. 
 
3.2.2. Injection protocols 
The animal experiments were performed as described in Figure 5. In brief, 2×106 of 
cancer cells were suspended in 350 µl of PBS and subsequently used for i. v. injection. 
For metastasis experiments, 500 µl solution of Matrixgel (Matrixgel : PBS=1:1) 
containing 2×105 cells were injected into the spleen capsule as described in Figure 6. 
Mice were sacrificed at the indicated time points, and the organs were collected for 
further analysis.  
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Figure 5 Time schedule of animal experiments with different mouse models 
  
41 
 
 
Figure 6 Time schedule of metastasis experiment. Picture shows the spleen capsule 
injection 
 
3.2.3 Preparation and storage of organs 
Organs were isolated from mice and washed with PBS twice at room temperature to 
remove traces of blood and other contaminants. Fixation of the organs was performed 
in 4% formalin solution for 2 h, and subsequently transferred to 30% sucrose solution 
for incubation overnight. All organs were stored at -80˚C before use.  
 
3.2.4 Cryosections 
Cryosections were obtained using a cryostat to freeze the tissue and to cut the frozen 
tissue for microscopic analyses. During the procedure, the rapid freezing of the tissue 
sample converts the water into ice that acts as embedding medium to cut the tissue 
118. The tissues were stored at -80˚C one day before being sectioned. The procedure of 
cryosections was performed strictly according to the instructions and resulted in 
sections ranging from 5-19 µm. The slides were stored at -20˚C. 
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3.2.5 Paraffin embedded sections 
The tissues were collected in plastic embedding cassettes and fixed in 4% formalin 
overnight, after which the cassettes were washed with distilled water. Then, the 
samples cassettes were incubated in a container with 70% ethanol for 1 day.  
Dehydration, clearing, and wax infiltration were done by an automated tissue 
processor. Finally, the tissues were manually embedded in paraffin. The paraffin 
embedded tissues were cut into 4 µm thick sections by a microtome. 
 
3.2.6 Cell culture 
The basic principle of the technique is to maintain cells isolated from various tissues 
of animals in an artificial (in vitro) environment that is suitable for cell viability and 
growth 119. The culturing conditions differ with every cell line. KCP cell lines were 
isolated from the pancreas of genetically modified mice that produce spontaneous 
metastasis, and were maintained in a high glucose/Dulbecco`s modified Eagles 
medium (DMEM, 4.5g/l) containing 2.5% NEAA and 10% fetal bovine serum (FBS). 
The primary pancreatic tumor-derived cell lines used were:  5320, 16990, S134, 
53631, 8028, 8182, 8305, 8570, 8661, 9091 and 9203 (kindly provided by Prof. Dr. 
Roland Rad (Technical University, Munich)), and were cultured in DMEM medium 
containing 10% FBS. The cells were grown in cell culture flasks of various sizes 
containing appropriate amounts of culture medium as stated in the catalogue. All cells 
were cultivated in presence of 100 units/ml penicillin and 0.1 mg/ml streptomycin at 
20% O2, 5% CO2 and 37°C.  
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3.2.7 Splitting of cells 
The Trypsin-EDTA solution and media were pre-warmed in a 37°C waterbath. The 
culture medium was removed from the flask. Enough sterile PBS (5 ml for 25 cm2 
flask, 10 ml for 75 cm2 flask) was added into the flask to wash the cells and to remove 
any residual FBS in the culture media. The flask was tipped gently for a few times to 
rinse the cells and carefully remove the PBS. Appropriate amounts of trypsin-EDTA 
solution were added to cover the cells at the bottom of the flask, and incubated at 
37°C for 2-7 min until the cells were detached completely. Different cell lines 
required different trypsinization times. To avoid over-trypsinization that can severely 
damage the cells, it was essential to check the cells’ shape every few minutes. As soon 
as the cells were detached, full medium containing FBS was added to the flask to 
inactivate the trypsin. The trypsinised cells were collected in falcons and subjected to 
centrifugation at 1,500 rpm for 5 min. After removal of the suspensions, the cell pellet 
was re-suspended in PBS and pipetted into new flasks with full medium at the 
required split ratio (approx. 1:10). Cell counting was performed using Neubauer’s 
chamber before the experiments and the appropriate number of cells were seeded in 
respective plates. Media were changed every two days. To change the medium, the 
media were carefully removed from the flask into a waste pot, the medium was 
replaced with fresh pre-warmed culture medium. The compositions of the different 
media are described in 3.2.6. 
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3.2.8 Preparation of cell stocks 
Cells were collected in falcons and washed twice with ice-cold PBS. After 
centrifugation at 1,500 rpm for 5 min, the supernatant was removed by gently 
pipetting. The cell pellet was re-suspended in Cryoprotectant Medium (Ibidi Freezing 
Medium) to achieve a concentration of at least 2 x 106 cells per ml, after which the 
suspension was transferred into cryogenic tubes and stored in liquid nitrogen. 
For cell recovery, cryo-preserved cells were rapidly thawed in water bath at 37°C, 
resuspended in 10 ml pre-warmed full medium and pelleted by centrifugation at 1,500 
rpm for 5 min. After that, the cells were re-suspended in 5 ml of full medium and 
transferred into cell culture flask for further cultivation. The compositions of the 
different media are described in 3.2.6. 
 
3.2.9 Isolation of plasmid 
The plasmid was isolated by using the Promega kit that can be used to extract any 
plasmid from E. coli hosts. The kit works well when the size of plasmid is up to 
20,000 bp. After isolation and purification, the plasmid was used for automated 
fluorescent DNA sequencing without further manipulation.  
The LB medium in which the bacteria were grown was transferred to a 1.5 ml 
microcentrifuge tube. 100 µl of Cell Lysis Buffer was added and mixed by inverting 
six times. The color change of the solution from opaque to clear blue indicated 
complete lysis of the bacteria. The next step proceeded within 2 min. 350 µl of 
ice-cold Neutralization Solution was added and mixed thoroughly by inverting the 
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tube. The color of the solution changed to yellow when the neutralization was 
complete, and a yellow precipitate was formed. After the complete neutralization, the 
tube was centrifuged at a speed of 13,000g for 3 min. Subsequently, the supernatant 
resulting from the centrifugation was transferred to a PureYield minicolumn provided 
by the kit. The minicolumn was placed into a PureYield Collection Tube (provided in 
the kit), and centrifuged at maximum speed in a microcentrifuge for 30 sec. The flow 
through was discarded and the minicolumn was placed into the same PureYield 
Collection Tube. 200 µl of Endotoxin Removal Wash was added to the minicolumn, 
and centrifuged at maximum speed for 30 sec. The centrifugation was repeated again 
after addition of Column Wash Solution. Next, the minicolumn was transferred to a 
clean 1.5ml microcentrifuge tube, after which 30 µl of Elution Buffer was added 
directly to the minicolumn matrix and incubated for 1 min at room temperature. 
Finally, the plasmid was eluted by centrifugation for 20 sec. The isolated plasmid was 
stored in freezer until use.  
 
3.2.10 Transient transfection 
Lipofectamine 3000 was used for transfection of siRNA Slc9a2 (284094, Thermo 
Fisher Scientific) and control siRNA (AM4611, Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Cells were counted in Neubauer’s chambers and 
appropriate numbers of cells were seeded in 6-well plates to attain a confluence of 70% 
- 80% before the start of transfection. All reagents were warmed up to room 
temperature before the start. 5 µl of Lipofectamine 3000 was diluted in 125 µl of Opti 
MEM reduced serum medium (solution A). The master mix of siRNA was prepared 
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by diluting siRNA in 125 µl of Opti MEM reduced serum medium, followed by 
adding 5 µl of P3000 reagent (solution B). The diluted Lipofectamine 3000 reagent 
(solution A) and the master mix of siRNA (solution B) were mixed at a ratio of 1:1. 
After 15 min incubation at room temperature, the mixture was drop-wise added to the 
cells in 6-well plate containing 2 ml DMEM medium with 10% fetal bovine serum 
and 1% antibiotics. Cells were harvested and subjected to western blot 48 h-72 h after 
transfection. 
 
3.2.11 Stable transfection 
Stable transfection for shRNA was performed in principle as described above for 
transient transfection. Briefly, after 48 h transfection the appropriate antibiotic 
(Puromycin) was used to select the transfected cells. In order to eliminate the 
non-transfected cells, the selection was initiated with 3 μg/ml of antibiotic, followed 
by increasing concentrations (3-20 μg/ml) until no more dead cell were observed. The 
selected cell pool was maintained in full medium containing 10 μg/ml antibiotic. 
 
3.2.12 Puromycin selection 
Cells expressing the puromycin-N-acetyl-transferase (pac) gene were selected by 
puromycin. The recommended working concentration range for puromycin was 
0.5-10 µg/ml. Since the appropriate concentration of puromycin varies according to 
the cell type, cell survival curve was obtained to determine the optimal working 
concentration before the selection of pac-positive cells.  
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After transfection the cells were seeded in 0.5 ml full growth medium per well in a 
24-well tissue culture plate. The cell density of the adherent cells was 20,000/ml, 
while the density for suspension cells was 40,000 cells/ml. Cells were cultured 
overnight to attain 70% confluency before adding increased amounts of puromycin. 
As for example, 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, and 10.0 µg/ml of 
puromycin was added to duplicate wells of cells in complete growth medium (Figure 
7). For the no-antibiotic control, the same amount of distilled water was used. The 
culture medium containing puromycin was replaced every 2-3 days for up to 7 days. 
The signs of visual toxicity were examined every day, and three puromycin doses 
were determined: Low dose, optimal dose, and high dose. low dose, which means the 
puromycin concentration at which minimal visual toxicity is apparent after a week; 
optimal dose means the lowest puromycin concentration at which all cells were dead 
after a week; high dose means the puromycin concentration at which visual toxicity is 
evident within the first 2-3 days.  
 
Figure 7 Antibiotic selection to obtain stable transfected cell line. Numbers refer to 
the concentration of antibiotics 
 
3.2.13 Protein isolation 
Protein for western blot was isolated as described previously 120. In order to harvest 
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cells under nondenaturing conditions, cells were washed twice with ice-cold PBS. 
RIPA (Thermo Fisher Scientific, MA, USA) lysis buffer and a plastic cell scraper 
were used to harvest cells. After sonication, the lysates were centrifuged at 16,060 g 
for 20 min at 4°C in order to separate the protein from cell debris. Subsequently the 
supernatant containing protein lysate was transferred into a new tube.  
 
3.2.14 Protein estimation  
The concentration of soluble protein was estimated using the Bradford assay that is 
based on the reactions of protein with an alkaline copper tartrate and the folin.121 The 
Bradford reagent (DC™ Protein Assay Kit I, Bio-Rad) was diluted in distilled water 
as per manufacturer’s instructions. A standard protein solution of 2 mg/ml BSA was 
used to prepare serial dilutions ranging from 2 mg/ml to 0.03906 mg/ml of BSA 
(Figure 8). 500 µl PBS was used to re-suspend the samples. All samples and standards 
were analysed in triplicate and a negative control was included. 5 µl of the standards 
and samples were pipetted in triplicates onto 96-well plate. 25 µl of the alkaline 
copper-alkali-tartrate solution A, which forms a complex with the proteins in the 
suspension, was pipetted to each well before addition of 200 µl of folin solution B. 
After 15 min, the absorbance was read at 750 nm in a plate reader.  
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Figure 8 Serial dilutions of BSA. Numbers refer to the concentration of BSA 
 
3.2.15 SDS-PAGE and Western blot 
7.5% to 15% polyacrylamide protein gels were prepared depending on the size of the 
analyzed proteins and overlaid with 4% stacking gel. Subsequently, the cell lysate was 
mixed with loading buffer, and denatured at 95°C for 5 min. 20 µg of protein per 
sample was subjected to 7.5% to 15% SDS-acrylamide gels according to protein sizes. 
A commercial pre-stained protein ladder was used as size control.  
Separation of the proteins by electrophoresis was performed at 80-120 V in an 
electrophoresis unit (Invitrogen) with NuPAGETM MOPS SDS as running buffer. The 
separated proteins were transferred onto Immobilon PVDF membranes (Invitrogen) 
with NuPAGETM Transfer buffer using the Invitrogen blotting system and a BIO-RAD 
power supply constantly held at 125 mA and a maximum voltage of 10 V. 
In order to block unspecific protein binding, membranes were incubated for 1 h in 5% 
skim milk/TBS-Tween20 (TBS-T). Then, the membranes were incubated with the 
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primary antibodies (diluted in TBS-T) at 4°C overnight. After washing three times in 
TBS-T, the membranes were incubated with horseradish-peroxidase 
(HRP)-conjugated secondary antibodies for 1 h at room temperature. Then, 3 washing 
steps were conducted as described above. Enhanced Chemiluminescence (ECL, 
Thermofisher or Sigma) signals were recorded with film development machine for 
Western Blot (CURIX60, AGFA). The antibodies used here are listed in 3.1.3. 
 
3.2.16 Isolation of EVs 
EVs encompass vesicles that vary from 30 nm to 10 µm. Generally, the vesicles from 
non-apoptotic tumor cells are called large oncosomes (LOs) if the sizes of them are > 
1 μm, which can be detected directly by light microscopy. Tumor cells were cultured 
in vesicle-free medium till confluence and then the media were changed. After 3 d of 
changing media, the media were pooled and subjected to an initial centrifugation at 
350 g for 5 min (without brake). This was to remove the cells and their large debris. 
The supernatants were combined and centrifuged at 2,000g for 20 min (without brake). 
The pellets, which were suspended in PBS, while the supernatants were centrifuged at 
100,000g for 2 h in an ultra centrifuge. The pellets were suspended in PBS and the 
EVs stored at -20℃. 
 
3.2.17 Isolation and count of LOs 
Tumor cells were cultured in vesicle-free medium till confluence and then the media 
were changed. After 3 d of changing media, the media were pooled and subjected to 
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an initial centrifugation at 350 g for 5 min (without brake). This was to remove the 
cells and their large debris. Then, the amounts of LOs could count by light 
microscopy. 
 
3.2.18 Nanoparticle tracking analyses 
Before the start of the analyses, the ZetaView PMX 110 instrument was calibrated by 
polystyrol beads of a known concentration and diameter (100 nm). Post-acquisition 
parameters were set to a minimum brightness of 5, a resolution of 100 pixels and the 
frame rate was 30 frames/s. The isolated EVs were resuspended in PBS and 1 ml of 
the resuspension was injected into the machine with a syringe. Different dilutions 
were made in each sample to make sure that in each visual field the amount of EVs 
ranged from 100 to 200 particles, which is the ranges where the optimal accuracy of 
the measurement is achieved. The samples were measured at 11 different positions 
during 3 cycles of reading. The amount of EVs was calculated by the machine and 
exported as pdf file. 
 
3.2.19 FXa formation assay 
The formation of FXa is measured by a chromogenic assay to evaluate the 
procoagulant activity of the extrinsic pathway of the blood coagulation cascade. We 
prepared serial dilutions of the standard Thromborel-S in a 96-well plate. In each well 
of this 96-well plate 50 µl of CaCl2 (30mM) and 50 µl of standard or samples, which 
included 10,000 tumor cells dissolved in PBS, were added. A master mix of 
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chromogenic substance S-2222, Beriplex and the respective amount of resuspension 
buffer was prepared such that 100 µl of this mix was added to each well. S-2222 is 
cleaved by factor Xa which results in a color change that is detected at 405 nm. With 
the help of a plate reader (softMAXpro), the absorption was measured at 405 nm. 
Each 6 min, the absorption values were measured and the whole procedure lasted 6 
cycles. The final value was calculated by the plate reader and expressed as milliunits 
(mU)/ml. 
 
3.2.20 FXIIa formation assay 
The formation of FXIIa is measured by a chromogenic assay to determine the 
procoagulant activity of the contact pathway of the blood coagulation cascade. 85 μl 
samples, which included 10,000 tumor cells dissolved in Hepes buffer, were incubated 
with 85 μl master mix, consisting of 100 nM FXII and 100 μM ZnCl2, for 20 min at 
room temperature. In a 96-well plate, 10 μl of the chromogenic substrate S-2302 were 
added to each well and then 50 μl of the above mentioned samples were added. When 
S-2302 is cleaved by factor XIIa, this results in a color change that can be detected by 
ELISA detector at 405 nm. The plate reader (softMAXpro) measured the absorption 
of the samples for 120 min. 
 
3.2.21 TEG 
Thromboelastography (TEG) is a non-invasive method that quantitatively measures 
the global viscoelastic properties of whole blood clot formation 122. The principle of 
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the TEG in vitro test is to detect and quantify dynamic changes of the viscoelastic 
properties during clotting under low shear stress. The procoagulant activities of 
microvesicles, oncosomes, or cancer cells were tested by this technique using whole 
blood as a medium. The test was performed in a specially designed TEG pin and cup 
apparatus. Briefly, 250 µl of whole blood containing 60 µl of a solution of 30 mM 
CaCl2 and 30 µl of the sample with for example 10,000 tumor cells were added to 
each cup. The measurements were performed using the rotation thromboelastometry 
device from ROTEG. 
 
3.2.22 Immunohistochemistry: Immunostaining of cryosections 
Immunohistostaining is used to detect the localisation of specific antigens in tissue by 
the use of markers such as fluorescent dyes or enzymes based on antigen-antibody 
interactions 123.  
Cryosections (10-15 µm) were fixed in 2%-4% of formalin for 15 min at room 
temperature, and subsequently washed three times with PBS. To reduce the 
non-specific immunostaining, a blocking step was performed with 2% BSA in PBS 
for 1 h at room temperature. After washing twice with PBS, the diluted primary 
antibody was added to the section and incubated in a humidified chamber overnight at 
4˚C. The sections were rinsed twice with PBS, followed by an incubation with diluted 
secondary antibody for 1 h at RT. The excess of antibody was washed away with PBS. 
The sections were then mounted with glycerol and sealed with nail polish or mounting 
medium. The antibodies used here are listed in 3.1.3 and 3.1.4. The signals were 
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visualized with Confocal Laser Scanning Microscopy. Images were captured with a 
LSM700 microscope using the ZEN software (Zeiss). 
 
3.2.23 Immunostaining of cells in suspension 
Cells were harvested and centrifuged at 1,300 rpm for 5 min, and then re-suspended in 
PBS. The cell viability was counted using a Neubauer chamber with addition of 
trypan blue to identify dead cells. Cells with viability around 90%-95% were used for 
staining in sterile epicups. Then cells were fixed in 1% formaldehyde for 10 min at 
37˚C, 200 µl PBS was added to the cells and a pellet was obtained by centrifugation at 
1,300 rpm for 5 min. The pellets were re-suspended in PBS and centrifuged to remove 
the remaining formaldehyde. The primary antibody at an appropriate dilution, usually 
suspended in 200 µl PBS with 2% BSA, was added and the suspensions were 
incubated for 1-4 h at 37˚C with intermediate mixing. After incubation, the cells were 
washed three times with 200 µl PBS. The secondary antibody was diluted in PBS at a 
concentration of 2 µg/ml, and the cells were incubated with secondary antibody for 1 
h at 4˚C in dark with intermediate vortexing. Then, the cells were washed three times 
with PBS and centrifuged at 1,300 rpm for 5 min, subsequently stored in 100 µl of 
PBS in the dark until microscopic analysis. In principle, the same procedure as 
described above for cells was used for staining of vesicles. The washing steps for the 
EVs were adjusted to the type of particles. Microvesicles were centrifuged at 12,600 
rpm for 35 min whereas large oncosomes were centrifuged at 10,000 rpm for 35 min. 
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3.2.24 Immunostaining of adherent cells 
Cells were seeded on glass cover-slides in a 6-well plate. After cell culture, the cells 
were fixed in 4% paraformaldehyde/PBS for 10 min, permeabilized in 0.2% Triton 
X-100 for 20 min and blocked in 100% FBS for 30 min. The primary antibody (in 200 
µl PBS with 2% BSA) was added and incubated overnight with the samples. Then, 
the cells were washed three times with 200 µl of ice-cold PBS. The secondary 
antibody was diluted in PBS at a concentration of 2 µg/ml, and the cells were 
incubated with the antibody for 1 h at 4˚C in dark with intermediate vortexing. The 
cells were washed three times with PBS and centrifuged at 1,300 rpm for 5 min, and 
subsequently stored in 100 µl of PBS in the dark until microscopic analysis.  
 
3.2.25 Staining with long-lived fluorophore 
Cell-Tracker dyes (Invitrogen) were used for staining of tumor cells to monitor their 
movements and locations. The staining procedure was performed according the 
instructions. Briefly, 200 µl of PBS was used to suspend the tumor cells. A 40 µM 
working solution of the cell tracker dye pre-diluted from the stock was prepared in 
PBS and pre-warmed for 10 min at 37˚C. 200 µl of the dye solution was added to 
each cell sample to achieve a final concentration of 20 µM. The samples were mixed 
gently by pipetting and incubated at 37˚C for 30 min. After the incubation, the extra 
dyes were removed by centrifugation and washing of the cells with PBS. To be sure 
that the staining was successful, an aliquot of the stained samples was checked by 
fluorescence microscopy before injection. 
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3.2.26 Imaging and Image analysis 
Imaging of immuno-histochemistry samples was performed by confocal laser 
scanning microscopy. Fluorescence pictures were taken by using a Zeiss 510-CLSM 
system and with argon lasers to generate lower wavelength light beams and a 
combination of three helium-neon lasers for wavelengths above 500 nm. Several 
versions of the ZEN software (Blue 2009/ 2011; Black 2012) were used to analyse the 
pictures. 
 
3.2.27 Labelling of primary antibody 
Alexafluor-mAb labelling kit was used to label primary antibodies that had been 
raised in mouse. In co-staining procedures, one pre-labelled primary antibody was 
used to facilitate the use of two antibodies raised in the same animal. The labelling 
was performed according to the instructions. 50-100 µg of antibody was incubated 
with the labelling reagent for 3 h at room temperature. In order to remove the extra 
dyes in the solution, the labelled antibody was recovered using Zeba spin columns 
equilibrated with the respective buffers according to the instructions of the 
manufacturer. 
 
3.2.28 Total RNA extraction 
Total RNA was extracted from the cells using the NucleoZOL reagent  
(MACHEREY-NAGEL, REF 740404.200) according to the manufacturer’s 
instructions. Briefly, the cell culture medium was removed, followed by adding 500 μl 
57 
 
of NucleoZOL and 200 μl of RNase-free water, respectively. The samples were 
shaken vigorously for 15 s and incubated at room temperature for 5 min. In order to 
obtain the supernatant containing RNA, the samples were centrifuged at 12,000 g for 
15 min. To precipitate RNA, 500 μl of supernatant was transferred to a fresh tube, and 
mixed well with 500 μl of isopropanol. After centrifugation at 12,000 g for 10 min, 
the supernatant was discarded. The white pellet at the bottom of the tube was washed 
three times with 70% ethanol (34852-M, Sigma) and the remaining ethanol was 
removed by pipetting. RNase-free water (AM9935, Invitrogen) was used to 
reconstitute RNA to obtain an RNA concentration of 1 μg/μl.  
 
3.2.29 RNA reverse transcription 
High-Capacity RNA-to-cDNA™ Kit (4387406, Thermo Fisher Scientific) was used 
for cDNA synthesis according the instructions of the manufacturer. 1 μg of total RNA 
isolated as described above was used for the reverse transcript reaction. The thermos 
cycle included 60 min incubation at 37°C, followed by a 65°C incubation for 10 min.  
 
3.2.30 Quantitative real-time PCR (qPCR) 
qPCR was performed with the PowerUp™ SYBR™ Green Master kit (A25741, 
Thermo Fisher Scientific) that is a pre-formulated, optimized, universal 2X master 
mix for real-time PCR workflows. 2 μl of cDNA per sample was used for the 
reactions. Expression of mRNA of the gene of choice was normalized to β-actin- or 
GAPDH-mRNA. The qPCR results were calculated using the ΔΔCt method124. 
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Results are represented as fold induction of the treated/transfected condition 
compared with the control condition. All experiments were performed in triplicates. 
All qPCR primers are listed in 3.1.9. 
 
3.2.31 Hematoxylin-eosin staining 
Hematoxylin and eosin stain is the most widely used stain in medical diagnosis. The 
staining method involves application of hemalum, a complex formed from aluminium 
ions and oxidized hematoxylin 125. Thereby nuclei are colored in blue. Subsequent 
counterstaining with an aqueous or alcoholic solution of eosin Y results in various 
shades of red, pink and orange. The tissues were hydrated in a series of decreasing 
concentration of ethanol, followed by incubation with Mayer’s hemalum solution 
(Merck)/Hematoxylin for 5 min. In order to blue the stain, the slides were washed 
under running tap water for three times. Next, the tissues sections were stained with 
eosin solution and subsequently subjected to dehydration again to fix them. After that, 
the slides were mounted in glycerol. 
 
3.2.32 Statistical analysis 
Statistical analysis was performed using ANOVA with a post hoc Bonferroni 
correction for comparisons between multiple groups. Two-tailed unpaired T-test was 
performed for the comparisons between two groups. P-values < 0.05 were considered 
as significant. Asterisks generally indicate: *P < 0.05, **P < 0.01, ***P < 0.001 and 
****P<0.0005. Mean values ± SEM (usually at least 3 biological replicates) are 
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provided.  
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4. Results 
4.1 Whole transcriptome analysis of tumor cell lines 
The RNA sequences of the 11 different pancreatic cell lines used in our study were 
compared. Analysis of the entire transcriptome of the cell lines was found to be 
overall identical as shown in the heatmap of Figure 9. 
 
 
Figure 9 Heat map of the RNA sequence analyses of 11 pancreatic cancer cell lines 
 
4.2 KRAS pathway analysis and correlation comparison  
Since the KRAS pathway is a crucial pathway for tumor invasion and metastasis, the 
expressions of gene implicated in this pathway were analyzed in particular. Genes 
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participating in the KRAS pathway were largely comparable across the 11 pancreatic 
cell lines (Figure 10). Correlation comparison indicated that the correlation between 
each of two cell lines were > 0.98, which suggested strong similarities between the 
cell lines (Figure 11). 
 
Figure 10 A Heat map for KRAS pathway gene expressions of 11 pancreatic cancer 
cell lines as determined by RNA-sequence analyses 
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Figure 11 Correlation comparison analyses for the expression of genes implicated in 
the KRAS pathway for 11 pancreatic cancer cell lines  
 
4.3 Procoagulant activities of pancreatic cancer cell lines 
The clotting time (CT) parameter in whole blood coagulation analyses by TEG was 
used to evaluate the procoagulant activities of the pancreatic cancer cell lines, using 
blood of different healthy donors. To evaluate the procoagulant activity, the ratios of 
CT values with tumor cells to CT values without tumor cells (PBS) were calculated 
(Figure 12a). A lower ratio indicates a higher procoagulant activity of the cancer cells. 
The cell line 8182 showed the highest procoagulant activity and cell line 9091 the 
lowest ability to activate coagulation (Figure 12b, c). Therefore, cell line 8182 was 
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chosen to study the relationship between tumor-induced blood coagulation and 
extravasation. 
 
 
Figure 12 CT values of different pancreatic cancer cell lines. a) The ratios of CT 
values with tumor cells to CT values without tumor cells in 11 different pancreatic 
cancer cells. N=3. (different blood donors; for each cell line) b) CT values of cell line 
8182 and control (PBS). c) CT values of cell line 9091 and control (PBS). The cell 
lines were added to whole blood from healthy donors. Dots indicate different healthy 
donors. *P < 0.05, **P < 0.01, *** P < 0.001, **** P<0.0005. Cell lines S143, 5230 
and 16990 were checked by doctoral candidates Magda-Lena Berchtold and 
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Maximilian Wieser. Cell lines 8028, 8661, 9203 were checked by doctoral candidate 
Raphael Denz. Cell lines 8570 and 5230 were checked by doctoral candidate Raphael 
Denz and by the author. 
 
4.4 Tumor-induced blood coagulation of cell line 8182  
4.4.1 Role of FXII  
FXIIa, which plays an important role in the contact pathway of blood coagulation,29 
was detected by a chromogenic assay. FXIIa formation was not affected by cell line 
8182 (Figure 13a). Moreover, when cell line 8182 was added to normal plasma as 
well as to FXII deficient plasma (Figure 13b), the CT values were similarly shortened 
in normal plasma and FXII deficient plasma. Together, this indicated that the 
procoagulant activity of 8182 was not dependent on FXII. 
 
Figure 13 a) FXIIa formation chromogenic assay in presence of cell line 8182. b) CT 
values obtained using TEG with cell line 8182 in normal plasma and FXII deficient 
plasma. Dots indicated different healthy donors. **P < 0.01, ns, not significant. 
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4.4.2 Role of platelets 
Since platelets are important promoters of clot formation, fibrin formation induced by 
cell line 8182 was measured in normal plasma and platelet-poor plasma (PPP). There 
was no significant difference in procoagulant activity of 8182 between the normal 
plasma and PPP, suggesting that the tumor-induced blood coagulation induced by cell 
line 8182 was independent of the presence of platelets (Figure 14). 
 
Figure 14 CT values in response to cell line 8182 in normal plasma and PPP. Dots 
indicate different healthy donors. **** P<0.0005, ns, not significant. 
 
4.4.3 Role of Phosphatidylethanolamine (PE)  
Since PE exposure could promote tumor-induced blood coagulation,126 we next 
measured the procoagulant activity of cell line 8182 without or with Duramycin, a PE 
inhibitor. Duramycin did not affect fibrin formation in whole blood as induced by 
8182 at a concentration of 10 µM (Figure 15). 
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Figure 15 Cell line 8182 was pre-incubated with Duramycin (10 µM) or vehicle 
(DMSO), added to whole blood and the CT values were measured. Dots indicate 
different donors. ns, not significant. 
 
4.4.4 Role of GAS6 in tumor-induced blood coagulation 
The results of RNA sequencing analyses of cell lines 8182 and 9091 were compared 
using bioinformatics tools to search for potential genes responsible for tumor-induced 
blood coagulation, given that the procoagulant activities of these two cell lines differ 
dramatically. In M-A plots, any mRNA expression being increased more than 16-fold 
in 8182 vs. 9091 was highlighted in red. The Gas6 gene stood out since it was among 
the strongly increased genes in 8182 (Figure 16a) and since it is known to trigger 
blood coagulation.127 Hence we evaluated the role of GAS6 for the coagulation 
competence of cell line 8182. Cell line 8182 was pre-incubated with neutralizing 
anti-GAS6 antibody or isotype control antibody. Inhibition of GAS6 did not alter the 
procoagulant activity of cell line 8182 (Figure 16b). 
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Figure 16 a) The expression matrix of the RNA sequence analyses of cell lines 8182 
and 9091 were transformed into log2 format and a M-A plot obtained by subtracting 
the log2 value of 8182 from that of 9091. The expressions of genes with values above 
4 or below -4 with more than 16-fold changes are highlighted in red. b) Cell line 8182 
was pre-incubated with anti-mouse GAS6 neutralizing antibody (40 µg/ml) or isotype 
control antibody and CT values in whole blood were measured. Dots refer to different 
donors. ns, not significant. 
 
4.4.5 Role of TF 
To examine whether TF was involved in the procoagulant activity of 8182, first the 
cell line was analyzed for an eventual TF expression by immunofluorescence (IF). 
The cell membrane of 8182 expressed substantial TF (Figure 17a). Then FXa 
formation was measured by a chromogenic assay, which reflects the ability of the 
cells to trigger the TF pathway. Cell line 8182 strongly stimulated factor Xa formation 
(Figure 17c). Moreover, after pre-incubation of the cells with anti-TF neutralizing 
antibody, the CT value of whole blood was increased compared to that obtained with 
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the isotype control antibody, indicating that coagulation activity was reduced after TF 
blockage (Figure 17d). Together, these results showed that 8182 stimulated 
coagulation mostly via TF. 
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Figure 17 a) Representative IF images of 8182 cells stained with Phalloidin-FITC 
(green), anti-mouse TF antibody (1H1 red), DAPI (blue). Magnification fold x630. 
Scale bar, 10 µm. b) Representative IF images of 8182 cells stained with 
Phalloidin-FITC (green), anti-mouse IgG isotype antibody (red), DAPI (blue). 
Magnification fold x630. Scale bar, 10 µm. c) FXa formation assay with cell line 
8182. d) Cell line 8182 was pre-incubated with anti-mouse TF antibody (1H1 1:100) 
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or isotype control antibody and CT values were measured (TEG). Dots indicate 
different donors. **P < 0.01, *** P < 0.001, **** P<0.0005. 
 
4.4.6 Fibrin formation by cell line 8182 in vivo 
As indicated by the in vitro results, stimulation of blood coagulation by cell line 8182 
was dependent on TF and independent of FXII. To analyze the coagulation 
competence of 8182 in vivo, the cell line 8182 was injected into wild-type (WT) and 
f12-/- mice. At 2 h and 6 h, the mice were sacrificed to perform fibrin analysis in the 
liver microcirculation. Following injection of the cancer cells, fibrin depositions were 
visible in WT animals (Figure 18a). In f12-/- mice, fibrin production were unchanged. 
This suggested that the tumor-induced coagulation was strong enough to override 
host-induced blood coagulation (Figure 18a, b). Based on this conclusion, cell line 
8182 was employed further to study tumor-induced blood coagulation in vivo.  
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Figure 18 Fibrin formation analysis in the liver microcirculation after injection of 
8182 cells. a) Representative picture showing liver micro-vessels (blue line), 
identified by Stab II, and intravascular fibrin (red line). Scale bar, 10 μm. b) 
Quantitative measurement of fibrin formation in micro-vessels of the liver. The 
fibrin-covered area in the micro-vessel was calculated as part of the total micro-vessel 
area. n=3 (different mice), ns, not significant. 
 
4.4.7 Effect of 8182-triggered tumor-induced blood coagulation on tumor cell 
extravasation 
4 h after administration of factor Xa inhibitor by Rivaroxaban or vehicle (DMSO), 
cell line 8182 was injected into WT mice. 6 h later, microvascular fibrin formation 
was noticeable in vehicle-treated group, consistent with the results in Figure 4.10b. 
Fibrin formation was decreased in the Rivaroxaban-treated group. Approximately 80% 
of tumor-induced blood coagulation could be inhibited by Rivaroxaban (Figure 19).  
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Figure 19 Effect of Rivaroxaban on microvascular fibrin formation. 4 h after vehicle 
(DMSO) or Rivaroxaban treatment of WT mice, cell line 8182 was injected. 6 h later 
fibrin analysis on liver tissue was performed. Dots indicate different animals. **** 
P<0.0005. 
 
Next we analyzed the extravasation of the cancer cells at the same time point. 3D 
reconstruction made by Imaris (Figure 20a) showed that tumor cell extravasation had 
occurred after 6 h. With this approach, extravasation could be measured under 
different conditions (8182 injection alone, 8182 + vehicle (DMSO), 8182 + 
Rivaroxaban). In the Rivaroxaban treatment group, tumor cell extravasation was 
massively increased compared to the control (Figure 20b), potentially suggesting that 
tumor-induced blood coagulation might reduce tumor cell extravasation. 
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Figure 20 Effect of tumor-induced fibrin formation on tumor cell extravasation. a) 
Representative picture and 3D reconstruction of tumor cell extravasation. 
Micro-vessel (green), tumor cells (red), DAPI (blue). Scale bar 1 μm. b) Quantitative 
measurement of tumor cell extravasation. Dots refer to different animals. *** P < 
0.001, ns, not significant. 
 
4.4.8 Effect of 8182-induced blood coagulation on non-classical monocyte 
recruitment 
After 4 h of administration of Rivaroxaban or vehicle (DMSO), cell line 8182 was 
injected into WT mice. 6 h later, the recruitment of different immune cells was 
examined. Recruitment of non-classical monocytes (visualized as shown in Figure 
21a) was markedly reduced after Rivaroxaban treatment (Figure 21b), probably due to 
a suppressed tumor-induced blood coagulation. Indeed, fibrin production was 
diminished by approximately 80% due to Rivaroxaban (4.4.7 Figure 19).    
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Figure 21 a) Representative picture of a non-classical monocyte (CX3CR1high Ly6Clow) 
in the liver microcirculation. CX3CR1 (green), Ly6C (red), DAPI (blue). Scale bar 5 
μm. b) 4 h after vehicle (DMSO) or Rivaroxaban treatment in WT mice, cell line 
8182 was injected. Non-classical monocytes in the liver micro-vessels were counted 6 
h later by IHC. Dots refer to different animals. * P < 0.05, ns, not significant. 
 
4.4.9 Effect of non-classical monocytes on tumor cell extravasation 
Nur77-/- mice lack non-classical monocytes.128 To understand whether non-classical 
monocytes affect tumor cell extravasation, we injected cell line 8182 into Nur77-/- 
mice and respective WT mice. Tumor cell extravasation increased 6 h after injection 
of 8182 into Nur77-/- mice as compared to WT mice, suggesting that non-classical 
monocytes can reduce tumor extravasation (Figure 22).  
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Figure 22 Tumor cell extravasation in WT and Nur77-/- mice 6 h after injection of 
cell line 8182. Dots refer to different animals. ** P < 0.01.  
 
Ang-1 is an important regulator of tumor cell extravasation. Since Ang-1 can activate 
Tie-2 receptors which in turn promote the survival of endothelial cells, the 
maintenance of an endothelial barrier and a quiescent vasculature. We observed that 
Ang-1 was expressed in non-classic monocytes, as arrested in the liver 
microcirculation in response to the appearance of 8182 (Figure 23).  
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Figure 23 Representative picture of a non-classic monocyte expressing of Ang-1. 
Ly6C (green), CX3CR1 (orange), Ang-1 (red), DAPI (blue). Scale bar, 1 μm. 
 
4.4.10 Effect of tumor-induced blood coagulation on CD4+ T cell recruitment 
Fibrin deposition can be reduced by about 80% by Rivaroxaban, as shown in Figure 
19. CD4+ T cells have been reported in the literature to reduce the permeability of 
blood vessels during malignancy129. We found that reduction of tumor-induced blood 
coagulation by Rivaroxaban decreased recruitment of CD4+ T cells (Figure 24a, b). 
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Figure 24 a) Representative picture of a CD4+ T cell as arrested in the liver 
microcirculation. CD4+ (green), DAPI (blue). Scale bar, 5 μm. b) In WT mice treated 
with Rivaroxaban, cell line 8182 was injected and CD4+ T cells in liver tissue were 
counted 6 h after tumor cell injection. Dots refer to different animals. * P < 0.05, ns, 
not significant. 
 
4.4.11 Effect of 8182 on macroscopic liver metastasis 
3 weeks after injection of the cancer cell line 8182 into the spleen capsule, livers were 
harvested. No metastasis could be detected by inspection (Figure 25a) and under the 
microscope (Figure 25b). Microscopic thrombi were detected, however, in each visual 
field, indicating that prothrombolic mechanisms had been provoked by the tumor 
cells.  
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Figure 25 a) Macroscopic visualization of the liver 3 weeks after injection of cell line 
8182 into the spleen capsule. b) HE staining of the liver showing thrombi without 
metastasis. Magnification, x100 
   
4.5 Host-induced blood coagulation activation and tumor cell extravasation 
4.5.1 Host-induced blood coagulation as triggered by cell line 9091 
Cell line 9091 completely lacks prothrombotic activity (Figure 12). In order to 
examine whether the host triggers blood coagulation in response to 9091, cell line 
9091 was injected into wild type (WT) mice and f12-/- mice. After 2 h and 6 h, the 
mice were sacrificed to perform fibrin analysis in the liver microcirculation. As 
shown in Figure 26, fibrin production was substantially higher in WT mice compared 
to f12-/- mice. This suggested the existence of host-induced blood coagulation, which 
can be triggered by FXII. Moreover, fibrin formation in WT after vehicle injection 
was similar to fibrin formation in FXII deficient mice after tumor injection (Figure 
26), suggesting that the host-induced blood coagulation was completely 
FXII-dependent. From this experiment, we assumed that there was a host-induced 
blood coagulation, which was completely FXII-dependent.  
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Figure 26 Quantitative determinations of fibrin in micro-vessels of the liver in WT 
and f12-/- mice injected with 9091. The fibrin-covered area in the micro-vessel was 
calculated as part of the total micro-vessel. n=3, ** P < 0.01, ns, not significant. 
 
4.5.2 Effect of 9091 on tumor cell extravasation 
After 4 h Rivaroxaban treatment, cell line 9091 was injected into WT mice. 6 h later, 
fibrin deposition in liver was clearly noted in the vehicle-treated group, consistent 
with the results in Figure 26, while it was significantly decreased in the 
Rivaroxaban-treated group (Figure 27a). As indicated in 4.5.1, the blood coagulation 
after injection of 9091 is exclusively host-induced. Thus, Rivaroxaban can inhibit the 
majority of host-induced blood coagulation (Figure 27a). Next tumor cell 
extravasation was measured in absence and presence of the FXa inhibitor. 6 h after 
Rivaroxaban treatment, extravasation of 9091 was increased, suggesting that 
host-induced blood coagulation might reduce tumor cell extravasation (Figure 27b).  
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Figure 27 a) 4 h after treatment with Rivaroxaban treatment, cell line 9091 was 
injected into WT mice and fibrin analysis on liver tissue was performed 6 h later. b) 
Quantitative determinations of extravasation of 9091. Dots refer to different animals. 
** P < 0.01. 
 
4.5.3 Recruitment of non-classical monocytes and CD4+ T cells in Rivaroxaban 
treated mice supplemented with 9091 
Arrest of non-classical monocytes and of CD4+ T cells was measured in both vehicle 
(DMSO) and Rivaroxaban-treated animals receiving 9091. No difference was 
detected (Figure 28a, b).  
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Figure 28 4 h after vehicle (DMSO) or Rivaroxaban treatment of WT mice, cell line 
9091 was injected and the arrest of non-classical monocytes (a) and of CD4+ T cells 
in the liver microcirculation was determined. Dots refer to different animals. ns, not 
significant. 
 
4.5.4 The effect of FXII on extravasation of 9091 
After injection of cell line 9091 into WT and f12-/- mice, tumor cell extravasation was 
measured at 6 h. Tumor cells invasion into the perivascular tissue was higher in f12-/- 
mice compared to WT mice, indicating a suppressive role of FXII on tumor cell 
extravasation (Figure 29a). 9 h after tumor cell injection, extravasation of 9091 was 
still higher in f12-/- mice than in WT mice (Figure 29b). 
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Figure 29 Tumor cell extravasation 6 h (a) and 9 h (b) after injection of 9091 in WT 
mice and f12-/- mice. Dots refers to different animals. * P < 0.05, ** P < 0.01. 
 
4.5.5 Effect of FXII-deficiency and Rivaroxaban on neutrophil recruitment 
The number of neutrophils arrested in the liver microcirculation in response to 
injection of 9091 was increased by Rivaroxaban (Figure 30a). Since Rivaroxaban 
inhibits coagulation and only host-induced blood coagulation was present in mice 
injected with cell line 9091, host-induced blood coagulation might prevent neutrophil 
recruitment. In order to corroborate this conclusion, the number of neutrophils in liver 
was compared in WT mice and f12-/- mice. The arrested neutrophils in the liver 
microcirculation were increased in f12-/- mice (Figure 30b). Taking together, it is 
plausible to assume that host-induced blood coagulation might decrease the 
recruitment of neutrophils 
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Figure 30 a) Effect of Rivaroxaban treatment in WT mice supplemented with cancer 
cell line 9091 on arrest of neutrophils in the liver microcirculation (6 h). b) Neutrophil 
recruitment in WT and f12-/- mice 6 h after injection of cell line 9091. Dots refer to 
different animals. * P < 0.05.  
 
4.5.6 NETs formation and tumor extravasation 
The emergence of NETs was examined 6 h and 9 h after injection of tumor cell line 
9091 into WT mice. At 6 hours, no NETs were observed. Nonetheless, at 9 h NETs 
formation was clearly visible (Figure 31a-c). NETs could be seen in the vicinity of 
single neutrophils or around clusters of neutrophils (Figure 31b). Next, extravasation 
of 9091 was determined at 6 h and 9 h. At 9 h, extravasation of 9091 was elevated 
compared to 6 h (Figure 31d). In subsequent experiment, before injection of 9091, 
DNaseI was administered to degrade NETs. DNaseI treatment strongly reduced NET 
formation in response to cell line 9091 (Figure 31e). Concomitantly, tumor cell 
extravasation was markedly diminished by DNaseI (Figure 31f). This suggested that 
formation of NETs may support tumor cell extravasation. 
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Figure 31 a) Representative picture of a single neutrophil with NETs in WT mice 
injected with 9091. MPO (green), H3 cit (orange), DAPI (blue). Scale bar 10 μm b) 
Representative picture of neutrophil aggregates with NETs. MPO (green), H3 cit 
(orange), DAPI (blue). Scale bar 10 μm c) NET formation at 6 h and 9 h in 
9091-supplemented WT mice. d) Extravasation of 9091 at 6 h and 9 h in WT mice. e) 
Formation of NETs after DNase I treatment at 9 h in 9091-supplemented WT mice. f) 
Extravasation of 9091 after DNaseI treatment (9 h, WT mice). Dots refer to different 
animals. *P < 0.05, **P < 0.01, **** P<0.0005. 
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4.5.7 Potential underlying mechanism of the influence of NETs on tumor cell 
extravasation 
Since NETs can induce vessel occlusion and blood flow stop,130 we were interested in 
whether NETs formation in response to tumor cells was associated with signs of 
hypoxia. HIF1α is a marker of hypoxic areas. Thus fluorescence intensities 
originating from HIF1α were measured 9 h after injection of 9091. As a result, clear 
HIF1α staining was observed which was mainly restricted to the endothelium. After 
treatment with DNaseI, HIF1α labeling was reduced (Figure 32b), potentially 
suggesting that NETs might increase hypoxic area. Next, the expression of Ang-1 and 
-2 were measured in the microvascular compartment. Indeed, both Ang-1 and Ang-2 
could be detected (Figure 32c, d). Following treatment of mice with DNaseI, the 
expression of Ang-1 was elevated while that of Ang-2 was decreased (Figure 32e). 
Thus, NET formation may up-regulate expression of Ang-2 and down-regulate Ang-1 
expression.  
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Figure 32 a) Representative picture of HIF1α staining in liver microvessels following 
injection of 9091. HIF1α, green, Stab II, orange, DAPI, blue. Scale bar, 10μm. Red 
arrow, expression of HIF1α. b) Fluorescence intensities of HIF1α staining in the liver 
microcirculation after DNaseI treatment. c) Representative picture of Ang-1 staining 
in endothelial cells. Stab II, green, Ang-1, orange, DAPI, blue. Scale bar, 1 μm. Red 
arrow, expression of Ang-1. d) Representative picture of Ang-2 staining in endothelial 
cells. Stab II, green, Ang-2, orange, DAPI, blue. Scale bar 1 μm. Red arrow, 
expression of Ang-2. e) Fluorescence intensities of Ang-1 and Ang-2 staining in liver 
micro-vessels after DNaseI treatment. Dots refer to different animals. *P < 0.05, **** 
P<0.0005 
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4.5.8 Effect of 9091 on macroscopic liver metastasis 
3 weeks after injection of cancer cell line 9091 into the spleen capsule, livers were 
harvested. Pronounced metastasis was observed in the liver by inspection (Figure 33 a) 
and by HE staining (Figure 33 b).  
 
 
Figure 33 a) Inspection of the liver 3 weeks after injection of cell line 9091. Presence 
of a large metastasis. b) HE staining of the liver showing metastatic niches (red 
arrows). Magnification: x100. 
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4.6 Role of cancer cell extracellular vesicles (EVs) for tumor cell extravasation 
4.6.1 Release of EVs by pancreatic cancer cell lines 
Apart from exosomes, there are two important subgroups of EVs that could be crucial 
to tumor invasion and metastasis, namely MVs and LOs. The release of LOs by 11 
different pancreatic tumor cell lines was evaluated by counting them in the tumor cell 
supernatant. Cell line 53631 had the strongest ability to produce LOs, while cell line 
8182 had the weakest (Figure 34a). Since nanoparticle tracking analyses can detect 
EVs < 1 μm, they were used to measure EV release by cell lines 53631 and 8182. As 
shown in Figure 34b, there were also clear differences in the amount of EVs released 
between 53631 and 8182. Thus, these two cell lines were used in the following 
experiment.  
 
Figure 34 a) Release of LOs in 11 different pancreatic cell lines measured as 
determined by light microscopy in the tumor cell supernatant. N=3, **** P < 0.0005. 
b) Release of EVs by cell lines 53631 and 8182 as detected by nanoparticle tracking. 
N=3. Dots refer to different biological repeat of nanoparticle tracking. ** P < 0.01. 
89 
 
4.6.2 Bioinformatic analyses to search for genes responsible for EV release 
In order to search for genes potentially responsible for EV release, bioinformatic 
analyses of the transcriptomes of cell lines 53631 and 8182 were performed. Any 
difference between 53613 and 8182 in gene expression that was greater than 16-fold 
was highlighted in red in the M-A plot showing in Figure 35a. Among such genes was 
Padi4 which was previously reported to promote release of LOs.131 Additionally, the 
mRNA expressions of all 11 pancreatic cell lines were analyzed and over 20,000 
genes were classified into 20 different subgroups (Figure 35b). Padi4, the gene of 
interest, was in profile 10 with another 5 genes. The correlation coefficients between 
these 5 genes were calculated and shown through a heatmap (Figure 35c). The 
expression of Slc9a2 stood out with a coefficient correlation of 0.94 to Padi4 
expression. Moreover, the fold change of Slc9a2 was over 4 according to the M-A 
plot in Figure 35d. 
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Figure 35 a) Comparison of the RNA expression matrix between cell lines 53631 and 
8182. The gene names, with values above 4 or below -4 (log2 format) are highlighted 
in red, indicating more than a 16-fold difference.  b) Gene expression trends of 11 
pancreatic cell lines. The profiles are reordered based on actual size based p-value 
enrichment for genes. c) Correlation coefficients between the 5 genes in profile 10 in 
gene expression trends analyses. d) M-A plot of cell line s53631 and 8182. Padi 4 and 
Slc9a2 are highlighted in red. 
 
4.6.3 Validation of Padi4 - Slc9a2 association by qPCR and WB 
qPCR of Padi4 and Slc9a2 were performed for cell lines 53631 and 8182. The 
fold-increase of Padi4 mRNA expression was around 1,500 and of Slc9a2 mRNA 
expression was about 6000 for cell line 53631 compared to cell line 8182 (Figure 36a, 
b). On the protein level, PADI 4 expression was about 25 times higher in cell line 
53631 than in 8182, while the expressions of SLC9A2 were comparable between the 
two cell lines (Figure 36c, d). 
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Figure 36 a) Padi4 mRNA expressions of cell lines 8182 and 53631 (qPCR). N=6, 
****P<0.0005. b) Slc9a2 mRNA expressions of cell lines 8182 and 53631 (qPCR). 
N=6, ****P<0.0005. c) Representative WB images of PADI4 in cell lines 8182 and 
53631. Densitometric quantification of WB analyses (right). N=4, ****P<0.0005. d) 
Representative WB images of SLC9A2 in cell line 8182 and 53631. Densitometric 
quantification of WB analyses (right). N=4, ns: not significant. 
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4.6.4 Padi4 knockdown in cell line 53631 by shRNA 
After transfection of the 53631 cell line with Padi4 shRNA and antibiotic selection, a 
stable transfected cell line was established. On the mRNA level, Padi4 expression was 
markedly decreased compared to non-target shRNA transfected cells (Figure 37a). On 
the protein level, the expression of PADI4 was clearly reduced as well. However, this 
lowering of PADI4 had no effect on the SLC9A2 expression (Figure 37b, c). 
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Figure 37 a) Padi4 mRNA expression in Padi4 shRNA stable transfected 53631 cells, 
and mock shRNA transfected 53631 cells. N=3, ** P < 0.01. b) Representative WB 
images for PADI4 expression in Padi4 shRNA stable transfected 53631 cells and 
mock shRNA transfected 53631 cells (left). Densitometric analyses of PADI4 in 
Padi4 shRNA stable transfected 53631 cells (right). N=3, ** P < 0.01.  c) 
Representative WB images for SLC9A2 in Padi4 shRNA stable transfected 53631 
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cells (left). Densitometric analyses for SLC9A2 expression in Padi4 shRNA stable 
transfected 53631 cells. N=3, ns, not significant.  
 
4.6.5 Release of EVs from Padi4-shRNA-transfected 53631 cells 
In Padi4-shRNA-transfected 53631 cells, release of LOs and EVs were strongly 
reduced as measured by light microscopy and with nanoparticle tracking analysis, 
respectively compared to that of mock shRNA transfected 53631 cells (Figure 38a, b). 
 
Figure 38 a) Release of LOs from Padi4-shRNA-transfected 53631 cells. b) Release 
of EVs from Padi4-shRNA-transfected 53631 cells. N=3, ** P < 0.01. 
 
4.6.6 Procoagulant activities of Padi4-shRNA-transfected 53631 cells 
The procoagulant activities in mock shRNA-transfected 53631 cells and 
Padi4-shRNA-transfected 53631 cells were compared. As shown in Figure 39, there 
was no significant difference between these two cell lines. Thus, changes in 
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procoagulant activities can be excluded if the mock- and Padi4-shRNA-transfected 
53631 differ in their extravasation behavior. 
 
Figure 39 CT values (TEG) of mock- and Padi4-shRNA-transfected 53631cells. Dots 
refer to different donors. ns, not significant. 
 
4.6.7 Role of EV release on tumor extravasation 
As shown in 4.6.5, the release of EVs strongly decreases after Padi4 down-regulation 
in cell line 53631. To examine the role of EV release for tumor cell extravasation, 
both mock- and Padi4-shRNA-transfected 53631 cells were injected into WT mice 
and after 6 h tumor cell extravasation was analyzed in the liver microcirculation 
(Figure 40). Extravasation of Padi4-shRNA-transfected 53631 cells was higher than 
the mock-shRNA-transfected 53631 cells, suggesting that the ability to release EVs 
increases tumor cell extravasation. 
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Figure 40 Numbers of Padi4-shRNA-transfected 53631 cells extravasated in the liver 
microcirculation after 6 h of cancer cell injection. Dots refer to different animals. ** P 
< 0.01. 
 
4.6.7 Role of tumor-induced blood coagulation and of EV release for tumor cell 
extravasation 
The amounts of non-classical monocytes and CD4+ T cells were counted in the liver 
microcirculation. There were no apparent differences between mock- and 
Padi4-shRNA-transfected 53631 cells for both immune cell species (Figure 41a,b). 
Some of the non-classical monocytes were found to contain cancer cell-derived EVs 
(Figure 41c). Moreover, part of the non-classical monocytes expressed Ang-2 instead 
of Ang-1 (Figure 41d). 
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Figure 41 Recruitment of non-classical monocytes (a) and CD4+ T cells (b) after 
injection of mock- and Padi4-shRNA-transfected 53631 cells (6 h after injection). 
Dots refer to different animals. ns, not significant. c) Non-classical monocytes with 
engulfed tumor-derived EVs. CX3CR1, green, EVs, red, Ly6C, orange. Scale bar, 2 
μm; EVs are highlighted with red arrow. d) Non-classical monocytes with Ang-2 
staining. CX3CR1, green, Ang-2, red, Ly6C, orange. Scale bar, 2 μm. 
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5. Discussion 
Extravasation is a key step in the process of tumor metastasis. After intravasation, 
circulating tumor cells can seed the tissue at distant sites and subsequently form a 
metastatic niche.22, 23 Generally, a high primary tumor burden and the presence of 
circulating tumor cells are associated with an elevated risk for venous 
thromboembolism and activation of blood coagulation.31 However, the role of 
blood coagulation in tumor extravasation or metastasis has not been clearly 
elucidated so far. Hence it is the focus of this study. 
In my experiments, I have used several pancreatic cancer cell lines with KRAS 
mutations to check the role tumor-induced blood coagulation plays in tumor cell 
extravasation. With the help of RNA sequencing of these cell lines, the analyses of 
entire transcriptomes were accomplished. The transcriptomes of the all cell lines 
tended to be almost identical. Moreover, CT values were obtained by TEG 
measurement to evaluate the procoagulant activities of each cell line. The highest 
tumor-induced blood coagulation activity was present in cell line 8182, while the 
lowest was present in cell line 9091. Tumor-induced blood coagulation by cell line 
8182 was found to be completely dependent on the TF pathway in vitro and in 
vivo. Such strong tumor-induced blood coagulation could override even 
FXII-host-induced fibrin generation. Surprisingly, after inhibition of factor Xa by 
Rivaroxaban, the extravasation of 8182 was increased, suggesting an inhibiting 
role of tumor-induced blood coagulation on extravasation. The underlying 
mechanism is not fully clear at present.  
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It was observed that tumor-induced blood coagulation is associated with a 
recruitment of non-classical monocytes. The most important function of 
non-classical monocytes is to patrol the endothelium as part of a local innate 
surveillance under physiological conditions.56-58 In the present work, non-classical 
monocytes were found to express Ang-1. Ang-1 is known to activate the Tie-2 
receptor, which can promote the survival of endothelial cells, the maintenance of 
the endothelial barrier, and a quiescent vasculature.109, 110 Thus, non-classical 
monocytes expressing Ang-1 could potentially regulate the permeability of the 
endothelium, thereby reducing tumor extravasation. 
When tumor-induced blood coagulation was weak or even absent such as in cell 
line 9091, host-induced blood coagulation was well evident. It was found to be 
crucially dependent on coagulation FXII. Activation of FXII is dispensable in the 
process of hemostasis. Yet, FXII plays a more important role in both physiological 
and pathological thrombosis.29 Thus, cell line 9091 was selected to study 
FXII-host-induced blood coagulation, since this cell line lacked coagulation 
activity in vitro. Activation of coagulation observed in the presence of 9091 in 
vivo could be explained by an immune response of the host. Rivaroxaban was 
demonstrated to be able to inhibit FXII-host-induced coagulation in this model as 
well. Extravasation of 9091 was compared in WT and f12-/- mice. Tumor invasion 
of 9091 was substantially higher in f12-/- mice than in control mice. Rivaroxaban 
treatment eliminated the difference in extravasation between the two different 
mouse species, indicating that activation of FXII prevented extravasation by a 
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coagulation-dependent mechanism. Taken together, FXII-dependent blood 
coagulation, as triggered by the host (potentially by endothelial cells), reduces 
tumor extravasation. 
FXII-host-induced blood coagulation might impede tumor extravasation through 
additional mechanisms, as for example by reduction of neutrophil recruitment. 
Indeed, following Rivaroxaban treatment of mice injected with 9091, the amount 
of neutrophils in the liver microcirculation was elevated, suggesting a suppressive 
role of host-induced coagulation on neutrophil recruitment. Moreover, neutrophil 
levels in the liver microcirculation were significantly higher in f12-/- mice 
compared to WT mice. This also suggested that host-induced blood coagulation 
had suppressed neutrophil recruitment.  
The emergence of NETs was not observed until 9 h after injection of tumor cells, 
indicating a slow formation. These NETs were arranged as part of a NET-covered 
area in which several neutrophils were clustered. It is plausible that the formation 
of these areas can induce the obstruction of blood flow in microvessels.130 Such 
occlusion could potentially cause the formation of hypoxia areas. When HIF1α 
expression was employed to detect hypoxic areas, it was found to accumulate in 
association with endothelial cells. In hypoxia areas, the expression of Ang-2 can 
be increased,111, 112 which could promote vessel permeability (Figure 41). To sum 
up, upstream formation of NETs increases formation of hypoxic areas and results 
in Ang-2 expression by local endothelial cells, which could further support tumor 
extravasation. Of relevance for this process is the recruitment of neutrophils and 
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the subsequent formation of NETs. Indeed, DNaseI treatment which can dissolve 
NETs, reduced the hypoxic areas and simultaneously increased expression of 
Ang-1 and decreased Ang-2 expression. As a conclusion, host-induced blood 
coagulation might hinder tumor extravasation by reducing the arrest of neutrophils 
and the formation of NETs. 
The release of EV is a typical feature of most cancer cells and has been suggested 
to support metastasis. In my study, cell line 53631 had the strongest EV release 
activity among 11 different pancreatic cancer cell lines with KRAS mutations. 
Hence it was chosen to study the relationship between EV release and tumor 
extravasation. Transcriptomic analyses showed that the Padi4 gene was associated 
with the high EV release in 53631 cells. Suppression of Padi4 expression by 
shRNA showed that Padi4 was responsible for EV release. The Padi4 shRNA 
stable-transfected 53631 cells were used to perform animal experiments. It was 
clearly shown that the release of EV by cancer cells can increase tumor cell 
extravasation. 
Surprisingly, cell line 53631 had the second strongest abilities to enhance blood 
coagulation among all 11 cancer cell lines, consistent with a marked 
tumor-induced blood coagulation activity. The procoagulant activities of cell line 
53631 and 8182 were comparable. Yet, our hypothesis was challenged when cell 
line 53631 showed much higher tumor extravasation compared to that of 8182, 
although both had similar procoagulant activities. Why tumor-induced blood 
coagulation acted so differently in these two cell lines is still unresolved.  
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Thus it appears that EV-release and tumor-induced blood coagulation somehow 
cooperate to assist in tumor cell extravasation. It was reported that tumor 
cell-derived EVs can educate monocytes and, as a result, these cells can 
differentiate into tumor-associated macrophages, which in turn can increase tumor 
cell extravasation.132 We observed here that non-classical monocytes can be 
recruited by fibrin and we found that these monocytes were stimulated in response 
to tumor-induced coagulation. Also non-classical monocytes took up tumor cell 
derived EVs. Moreover, while some non-classical monocytes express Ang-2 in 
mice injected with mock-shRNA-transfected 53631 cells, this expression was absent in 
mice injected with cell lines 8182 and Padi4-downregulated cell line 53631. Both 
cell line 8182 and Padi4-downregulated cell line 53631 have a weak capacity to 
release EVs. On the other hand, the uptake of tumor cell-derived EVs by 
non-classical monocytes in the case of mice injected with cell line 53631 may 
cause the non-classical monocytes to express Ang-2 (Figure 42).  
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Figure 42 Scheme of the effect of tumor-induced blood coagulation on tumor cell 
extravasation. 
 
Prometastatic tumor cells are in general master survivor cells. Tumor-induced 
blood coagulation, by this logic, shouldn’t possibly prevent tumor cell 
extravasation. Yet, our results suggest that under some conditions tumor-induced 
blood coagulation can recruit non-classical monocytes, which appears beneficial 
for the host to reduce tumor cell extravasation through expression of Ang-1. The 
EVs originating from the tumor cells, on the other hand, may educate 
non-classical monocytes to act as prometastatic agents. As a result, non-classic 
monocytes lose their expression of Ang-1, and some of them express Ang-2, 
which might result in an increased vessel permeability and facilitation of tumor 
cell extravasation. 
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6. Summary 
Thrombotic diseases are often observed in tumor patients and a high tumor burden is a 
crucial independent risk factor for the development of venous thromboembolism 
which is in part due to the ability of tumor cells directly to trigger blood coagulation. 
In the present study it was shown that two different types of microvascular blood 
coagulation can be distinguished in mice exposed to circulating pancreatic tumor cells, 
namely tumor-induced blood coagulation and host-induced blood coagulation. 
Tumor-induced blood coagulation in the microcirculation of the liver was found to 
increase the recruitment of non-classical monocytes. These immune cells expressed 
Ang-1, which is able to impede tumor cell extravasation. Moreover, non-classical 
monocytes engulfed tumor-cell derived EVs. It appeared that, following ingestion of 
tumor-cell derived EVs, non-classical monocytes lost their expression of Ang-1. Some 
of them, on the contrary, now expressed Ang-2, which is known to facilitate tumor 
cell extravasation. The effect of FXII-mediated-host-induced blood coagulation on 
tumor cell extravasation varied according to the type of mice studied. FXII suppressed 
the recruitment of neutrophils, whereby formation of NETs was decreased and the 
tumor cell extravasation was diminished. On the other hand, formation of NETs 
increased local HIF1α expression and Ang-2 expression by endothelial cells, which 
favored tumor cell extravasation. Phenotypic screens based on several pancreatic 
cancer cell lines revealed Padi4 as candidate gene promoting EV release and Gas6 as 
candidate gene for tumor-induced blood coagulation. 
In conclusion, both tumor-induced blood coagulation and FXII-host-induced blood 
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coagulation can in principle inhibit extravasation of pancreatic tumor cells during 
early tumor metastasis. However, release of EVs by tumor cells and 
tumor-cell-induced NETs formation could overcome the suppressive influence of 
coagulation.  
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7. Zusammenfassung 
Bei Patienten mit Tumorerkrankungen werden oftmals thrombotische Erkrankungen 
diagnostiziert. Zusätzlich stellt eine hohe Tumorlast einen wichtigen unabhängigen 
Risikofaktor für die Entwicklung von venösen Thromboembolien dar, die teilweise 
auf die Fähigkeit des Tumors, die Blutkoagulation zu induzieren, zurückzuführen ist. 
In der vorliegenden Arbeit konnte gezeigt werden, dass in der Maus zwischen zwei 
verschiedene Arten der Blutkoagulation unterschieden werden können, die die 
Tumor-induzierte Blutkoagulation und Wirts-induzierte Blutkoagulation bezeichnen.  
Die Tumor-induzierte Koagulation verstärkte die Rekrutierung nicht-klassischer 
Monozyten. Diese Immunzellen exprimierten Ang-1, wodurch die Extravasation der 
Tumorzellen behindert wurde. Zudem inkorporierten nicht-klassische Monozyten EV, 
welche von der Tumorzelle abgegeben wurden. Jedoch verloren die nicht-klassischen 
Monozyten nach erfolgreicher Aufnahme der EV die Expression des 
Wachstumsfaktors Ang-1. Stattdessen zeigte sich anschließend bei einigen Zellen eine 
vermehrte Expression von Ang-2. Die mittels FXII verstärkte wirts-induzierte 
Koagulation bewirkte unterschiedliche Effekte in der Extravasation der Tumorzellen. 
FXII induzierte eine Unterdrückung der Rekrutierung von Neutrophilen, wodurch die 
Bildung von NETs abnahm und die Extravasation der Tumorzellen vermindert wurde. 
Die Bildung der NETs bewirkte einen Anstieg der Expression von lokalem HIF1α und 
der Expression von Ang-2 auf Endothelzellen, wodurch die Extravasation von 
Tumorzellen begünstigt werden könnte. Phänotypische Screens mit Pankreas 
Karzinom-Zelllinien ergaben Kandidaten Gene für Freisetzung von EV aus 
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Tumorzellen (Padi4) und für die Tumor-induzierte Koagulation (Gas6). 
Zusammenfassend kann gesagt werden, dass sowohl die Tumor-induzierte 
Blutkoagulation als auch die Wirts-induzierte Blutkoagulation die Extravasation von 
Tumorzellen in der frühen Phase der Metastasierung hemmen kann. Jedoch kann 
durch die Freisetzung von EV und durch die Tumorzell-induzierte Bildung der NETs 
die unterdrückende Wirkung der Blutkoagulation antagonisiert werden. 
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